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Abstract 
 Increased use of intrauterine contraception is desirable to achieve safe, highly effective, 
long-acting, and reversible means to prevent unintended pregnancy.  For most women, 
intrauterine device (IUD) contraception is a viable option for protection from an unplanned 
pregnancy.  Fear of pain during insertion is one barrier to IUD use.  The aim of this project was 
to identify best practice evidence for different types of interventions for the management of pain 
during IUD insertion.  Evidence for pain management strategies was critically appraised, and the 
most recent information synthesized into evidence-based recommendations to promote point-of-
care decisions.   
 
 
 
 
 
 
 
 
 
 
 
 
 
     
MANAGEMENT OF PAIN DURING INTRAUTERINE DEVICE 4 
 
Table of Contents                                                                                            
                                                                                                                                        Page       
Abstract…………………………………………………………………………………….…..….3                  
Table of Contents……………………………………………………………………..….…….….4                    
List of Figures…………………………………………………………………………….….……7                    
List of Tables……………………………………………………………………………….…..…7                      
List of Appendices………………………………………………………………….………..……7    
Background ………………………………………………………………………….……...….....8 
Literature Review…………………………………………………………………….……..….….9  
 Pain During IUD Insertion………………………………………………….………....….9 
 Pharmacological Interventions for Pain……………………………………………….…10  
 Non-pharmacological Interventions for Pain……………………………………………11
 Limitations…………………………………………………………………….…………11 
Purpose…………………………………………………………………………………………...12 
Evidence-based Practice Model: The Star Model of Knowledge Transformation…………..…12 
Methods…………………………………………………………………………………………..14 
 Rights of Human Subjects……………………………………………………………….14 
 Project Design……………………………………………………………………………14 
 Search Strategy…………………………………………………..………………………14 
 Data Collection…………………………………………………………………………..15 
 Data Synthesis ……………………………………………………………………………15 
Results……………………………………………………………………………………………16           
MANAGEMENT OF PAIN DURING INTRAUTERINE DEVICE 5 
 
                                                                                                                                        Page                                                                                                                                           
Discussion………………………………………………………………………………………..16 
Evidence Summary………………………………………………………………………16 
 Analgesia…………………………………………………………………….…..16 
  Ibuprofen…………………………………………………………….......18 
  Ketorolac…………………………………………………………….…...18 
  Nitrous Oxide……………………………………………………….…....18 
  Tramadol versus Naproxen Sodium……………………………………...19 
 Anesthesia…………………………………………………………….………….19 
  Lidocaine Topical Gel………………………………………………...….21 
  Lidocaine/Prilocaine Topical Cream………………………………...…..22 
  Lidocaine Infusion or Spray………………………………………..…....22  
  Lidocaine Block…………………………………………………..……..22 
Cervical Priming…………………………………………………………………………23 
  Nitroprusside and Nitroglycerin………………………….…………......25 
  Vaginal Misoprostol………………………………………………….....25 
  Oral Misoprostol……………………………………………………...…26 
Non-pharmacological Interventions…………………………………………………….27 
 Delayed Bladder Emptying…………………………………………………...…28 
 Aromatherapy……………………………………………………………..……..28 
 Pre-placement Counseling and Distraction……………………………………...28      
Implications for Practice…………………………………………………………………………29 
 Analgesia………………………………………………………….…………...…29 
MANAGEMENT OF PAIN DURING INTRAUTERINE DEVICE 6 
 
                                                                                                                             Page 
             Anesthesia………………………………………………………………..……30 
 Cervical Priming…………………………………………………………..……31 
 Non-pharmacological Interventions…………………………………………....33 
Translation into Guidelines……………………………………………………………………..33 
 Analgesia………………………………………………………………………..34  
 Anesthesia…………………………………………………………………….…34 
 Cervical Priming…………………………………………………………………34 
 Non-pharmacological Interventions……………………………….…………….35 
Significance to Advanced Nursing Practice………………………………………………..……35 
Dissemination……………………………………………………………………………………36 
Summary…………………………………………………………………………………………36 
Conclusion……………………………………………………………………………………….37 
References…………………………………………………………………………….………….38 
Appendices…………………………………………………….…………………………………45 
 
 
 
 
 
 
 
 
MANAGEMENT OF PAIN DURING INTRAUTERINE DEVICE 7 
 
List of Figures 
                                                                                                                                        Page 
Figure 1.  Star Model of Knowledge Transformation……………………………………………13 
 
List of Tables 
                                                                                                                                        Page 
Table 1.  Studies Evaluating Analgesia Used for Pain during IUD Insertion………………...…17             
Table 2.  Studies Evaluating Anesthetics for Managing Pain during IUD Insertion………..…..20   
Table 3.  Published Studies about Cervical Priming to Facilitate IUD Insertion…………….….24 
 
List of Appendices 
                                                                                                                                        Page 
Appendix A:  Evidence-based Management of Pain during IUD Insertion……………….…….45 
Appendix B:  Permission to Reproduce Star Model of Knowledge Transformation…..………..49 
Appendix C:  IRB Exempt Approval…………………………………………………...….…….50 
Appendix D:  Critical Appraisal Table …………………...…………………………............…..51 
Appendix E:  John Hopkins Hierarchy of Evidence Table……………………………...…….…52 
Appendix F:  Critical Appraisal Table of Included Studies……………………………………...53 
 
 
  
 
 
MANAGEMENT OF PAIN DURING INTRAUTERINE DEVICE 8 
 
Background  
Forty three million women in their childbearing years in the United States (U.S.) are at 
risk of unintended pregnancy (Guttmacher Institute, 2015).  Long-acting reversible contraceptive 
methods, including intrauterine devices (IUD), are safe and highly effective contraceptive 
methods (Centers for Disease Control and Prevention [CDC], 2013).  Failure rates for IUDs are 
less than one percent, and they can be used by women of all ages including adolescents and 
nulliparous women (CDC, 2013).  Usage rates of long-acting reversible contraceptives in the 
U.S. increased from 2.4 % in 2002 to 8.5 % in 2009 with most women relying on IUDs (Finer, 
Jerman, & Kavanaugh, 2012).  Increased use of IUDs is desirable to achieve safe, highly 
effective, long-acting and reversible means to prevent unintended pregnancy (Allen, Carey, 
Raker, & Matteson, 2014). 
Fear of pain during insertion of an IUD may deter women from choosing the IUD as a 
method of contraception (Finer et al., 2012).  Pain during insertion of an IUD can be associated 
with multiple causes including applying the tenaculum to the cervix to straighten the cervical 
canal, passing the uterine sound, inserting the IUD through the cervix, and myometrial 
contractions caused by the IUD irritating the uterine cavity (Allen, Bartz, Grimes, Hubacher, & 
O’Brien, 2009).  Pharmacological interventions for pain control during IUD insertion include 
analgesics, local anesthetics, and the use of prostaglandins to soften the cervix; however, there is 
wide variation in the use of these methods (Allen et al., 2009).  Other non-pharmacological 
considerations such as pre-insertion counseling, the setting for the procedure, or the confidence 
of the provider may influence a women's level of anxiety, possibly affecting her perception of 
pain and the overall experience (Gemzell-Danielsson, Mansour, Fiala, Kaunitz, & Bahamondes, 
2013).   
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Offering and providing pain relief during IUD insertion is usually at the discretion of the 
provider or site where the service is being provided (Akintomide et al., 2013).  Also, healthcare 
providers often underestimate patients' pain during IUD insertion (Maguire, Morrell, Westhoff, 
& Davis, 2013), and differ in their opinions on women's perceptions of pain or discomfort 
(Akintomide et al., 2013).  An understanding of the relationship between provider and patient 
perceptions of pain, as well as knowledge of techniques to ease IUD insertion-related pain can 
promote patient comfort and satisfaction with care.  Determining an optimal method for reducing 
pain during IUD insertion benefits both women and healthcare providers.  
Literature Review 
Management of pain during IUD insertion has the potential to improve usage rates for 
women seeking long-acting reversible contraception.  Factors affecting greater pain associated 
with IUD insertion will be discussed.  All articles selected for this review incorporate both 
pharmacological and non-pharmacological interventions for managing pain during IUD 
insertion.  Finally, limitations in the available literature will be addressed to highlight the need 
for this project. 
Pain during IUD Insertion 
Review of the literature identified that pain during IUD insertion is multifactoral and 
difficult to predict.  According to Hubacher et al. (2006) predictors of increased pain during IUD 
insertion include nulliparity, age greater than 30 years, lengthier time since last pregnancy or last 
menses, and not currently breastfeeding.  Allen et al. (2014) predicted pain to be greater based on 
history of no previous vaginal delivery, and difficulty of the procedure.  The authors also 
identified higher expected pain and lower self-reported pain tolerance to be variables predictive 
of increased pain.   
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The level of pain women experienced during IUD insertion varied in published studies.  
Mild to moderate pain is expected during IUD insertion, but for some women the pain is 
substantial (Gemzell-Danielsson et al., 2013).  A prospective study revealed 78% of nulliparous 
women rated IUD insertion pain as moderate to severe (Hall & Kutler, 2015).  Also, a proportion 
of parous women (11%) reported severe pain (Heikinheimo et al., 2010).  Strategies for effective 
pain management during IUD insertion are needed for these women.  
Pharmacological Interventions for Pain 
There are multiple reviews and opinions in the literature regarding available 
pharmacological interventions for managing pain during IUD insertion.  These include analgesia, 
local anesthesia, and cervical priming.  Nonsteroidal anti-inflammatory drugs (NSAIDs) may 
reduce cervical or uterine pain because they act to block the cyclooxygenase enzyme from 
producing prostaglandin, thereby inhibiting inflammation (Edmunds & Mayhew, 2014).  The 
analgesic action of nitrous oxide is thought to be from stimulation of endogenous endorphins, 
and possibly corticotrophins and dopamine, creating euphoria that makes the patient less aware 
of pain (Rosen, 2002).  Local anesthesia decreases pain by blocking nerve conduction and 
causing a loss of sensation (Edmunds & Mayhew, 2014).  Prior to insertion of an IUD, the use of 
a prostaglandin such as misoprostol causes dissolution of collagen fibers in the cervix and may 
decrease pain by dilating and softening the cervix (Allen et al., 2009).    
The use of analgesia with NSAIDs for IUD insertion-related pain is widespread 
(Gemzell-Danielsson et al., 2013), despite the lack of supporting evidence of their efficacy 
(Carusi & Goldberg, 2015).  Nitrous oxide has been used for years for procedural analgesia in 
outpatient settings and has recently been investigated as an approach to pain management in the 
context of IUD insertion (Singh et al., 2015).  Local anesthesia was found to be used more by 
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providers working in integrated reproductive health and contraceptive-only services compared to 
those in general practice (Akintomide et al., 2013).  An online U.S. based survey reported 40% 
of providers routinely used misoprostol for cervical ripening in nulliparous women, but there 
were wide variations in timing, dose, and route of administration (Gemzell-Danielsson et al., 
2013).  According to Pergialiotis, Vlachos, Protopappas, & Vlachos (2014), pain intervention 
options for placement of IUDs are conflicting and inconclusive.   
Non-pharmacological Interventions for Pain 
The literature also revealed non-pharmacological interventions for pain relief with IUD 
insertion including delayed bladder emptying, aromatheraphy, pre-placement counseling, and 
distraction during the procedure.  Cameron, Glassier, Cooper, & Johnstone (2013) investigated 
delayed versus immediate bladder emptying for IUD insertion, but found no significant 
difference in reported pain scores.  Use of aromatherapy as complementary treatment has been 
examined and shown to reduce anxiety associated with IUD insertion (Shahnazi, Nikjoo, 
Yavarikia, & Mohammad-Alizadeh-Charandabi, 2012).  Pre-placement counseling and 
distraction were also found to be effective at reducing anxiety (Bahamondes, Mansour, Fiala, 
Kaunitz, & Gemzell-Danielsson, 2014).  Further evaluation of additional interventions in 
managing IUD insertion-related pain is warranted. 
Limitations  
 No guidelines are available that detail standardized approaches to the problem of 
managing IUD insertion-related pain for those women requiring, or requesting a pain relief 
intervention (Bahamondes et al., 2014).  A Cochrane review (2009) which included trials from 
1974 to 2007 highlighted the need for an updated evaluation of interventions for pain with IUD.  
UpToDate, a premier web-based, evidence-based decision support resource provided limited data 
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on additional interventions for relieving IUD insertion pain (Carusi & Goldberg, 2015).  Patient 
anxiety about the procedure may contribute to higher levels of perceived pain, suggesting further 
exploration of interventions to decrease anxiety during the procedure is needed; however, no 
studies of the role of non-pharmacological reduction of anxiety have been published 
(Bahamondes et al., 2014).   
Purpose  
Fear of pain has an impact on women choosing an IUD for birth control.  Management of 
pain during IUD insertion has the potential to improve the outcome for women desiring long-
acting reversible methods of contraception.  A critical appraisal of the literature was conducted 
with the objective of identifying interventions for managing pain associated with the insertion of 
IUDs.  Evidence of pain management strategies was evaluated and the most recent information 
available since 2010 synthesized into evidence-based recommendations.  The aim of this project 
was to critically evaluate the evidence for various pain management strategies and formulate 
evidence-based recommendations to promote point-of-care decision-making (see Appendix A).   
Evidence Based Practice Model: The Star Model of Knowledge Transformation  
 The Star Model of Knowledge Transformation (Figure 1) was utilized for this project as 
it provided an organizing framework for systematically identifying and transforming the 
evidence into recommendations for practice.  This model uses five star points to organize the 
complexity and volume of available knowledge, and depicts five stages of knowledge 
transformation.  These stages of knowledge transformation include a) discovery research, b) 
evidence summary, c) translation to guideline, d) practice integration, and e) process outcome 
evaluation (Stevens, 2012).   
MANAGEMENT OF PAIN DURING INTRAUTERINE DEVICE 13 
 
 
 
 
 
 
 
 
 
 
 
 
Discovery represented the knowledge inquiry stage regarding available interventions for 
managing pain during IUD insertion.  The evidence summary stage combined all the findings 
from the research studies, and reduced the large amount of literature into a manageable form.  In 
this project, a critical appraisal of all studies that could answer the research question was done in 
order to identify strategies for the management of IUD insertion-related pain.  The evidence was 
translated to produce valid and reliable clinical recommendations to enhance the management of 
pain during IUD insertion.  Practice integration is crucial to verify the success of this project in 
establishing best-evidence recommendations for use by primary care providers in clinical 
practice; however, it is important to include not only the healthcare provider but also the patient 
and system outcomes in the final evaluation phase (Melnyk & Fineout-Overholt, 2010).  This 
portion of the model was outside the scope of this project; however, a future project is suggested 
to assess the usefulness and applicability of the recommendations.  
 
Figure 1. Star Model of Knowledge Transformation. "Copyrighted material 
(Stevens, 2012).  Reproduced with expressed permission" (see Appendix B). 
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Methods 
Rights of Human Subjects  
 As this project is an analysis of metadata available through published sources, there was 
no requirement for human protection review.  An Institutional Review Board (IRB) application 
was submitted per graduate school requirements, and exempt status was assigned.  A copy of 
exempt IRB approval is included in the manuscript (see Appendix C).   
Project Design 
A critical appraisal of the literature was conducted to identify evidence-based best 
practice for the management of pain for women having an IUD placed.  "An intellectual critical 
appraisal of a study involves a careful and complete examination of a study to judge its strengths, 
weaknesses, meaning, credibility, and significance for practice" (Grove, Gray, & Burns, 2015, p. 
365).  Guidelines for the critical appraisal included: examination of the expertise of the authors, 
reviewing the entire study, addressing the strengths and weaknesses of each study, and 
evaluating study findings to determine implications for practice.  A critical appraisal table was 
utilized to summarize and evaluate the findings from the appraisal (see Appendix D).  The 
evidence was ranked according to the John Hopkins nursing evidence based practice system for 
hierarchy of evidence table (see Appendix E).   
Search Strategy  
The goal of the search strategy was to identify studies published in the last five years.  
The databases utilized for the review included PubMed, CINAHL, Cochrane Database of 
Systematic Reviews, the Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov.  
The search for unpublished studies also included Google Scholar, and ProQuest Dissertation 
and Theses Global.  Database searches included the keywords 'intrauterine device', 'insertion', 
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and 'pain'.  The search was then further refined by combining context search terms "OR" and 
"AND."  Reference lists were also checked for additional studies to ensure all relevant articles 
had been identified.  Studies in languages other than English were excluded as resources for 
translation were limited.   
Data Collection 
Research studies selected for critical appraisal were based on the timeline of published 
work, population, condition of interest, interventions of interest, and comparison interventions of 
interest.  Articles published from 2010 to the present were selected for critical appraisal and 
evaluated based on their significance to the project topic of best practice pain interventions for 
IUD insertion.  The critical appraisal evaluated studies that included the outcome measure: 
perceived pain during IUD insertion.  The population focus for this project was women having 
any type of IUD inserted.  The interventions and comparison interventions of interest included 
studies that evaluated any type of pain reduction strategy, including pharmacologic or other 
intervention administered prior to or during IUD insertion.  
Data Synthesis 
Each grid of the critical appraisal table contains the following information: American 
Psychological Association (APA) citation, study method, population, variables, measurement, 
data analysis, findings, and level of evidence.  This allowed for comparative analysis of study 
design; number and characteristics of patients; type of intervention; scale used to measure 
outcome variable; statistics used to answer the clinical question and significance of pain 
reduction effect; statistical findings; and worth or feasibility of use in advanced nursing practice.  
To assess evidence quality and address confidence in the recommendations from this project, the 
John Hopkins nursing evidence based practice hierarchy of evidence was utilized to determine 
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the overall strength of each article included in the critical appraisal.  According to this hierarchy, 
systematic reviews of randomized control trials, experimental/ randomized controlled trials 
(RCT) or meta-analysis of RCTs are assigned a level I.  Level I is considered the strongest level 
and represents high-quality evidence.  
Results 
The initial search utilizing EBSCOhost resulted in 82 articles.  The title and abstract of 
each article was reviewed to determine if inclusion criteria were met, and duplicates were 
removed.  Of these, 26 studies were catalogued into the critical appraisal table (see Appendix F).  
Each article was fully read and individually reviewed paying careful attention to study design, 
validity of findings, and usefulness of the results.  An additional three relevant articles were 
identified from reference lists of articles reviewed.  Ultimately, a total of 29 studies were deemed 
appropriate for inclusion, all of which were of level I evidence.   
Discussion 
Evidence Summary 
The pharmacological interventions identified included the use of analgesia, local 
anesthesia, and cervical priming.  Strategies for non-pharmacological pain management included 
delayed bladder emptying, aromatherapy, psychological preparation/counseling before insertion 
and distraction during the procedure.  The evidence for each of these strategies and implications 
for practice are presented.    
 Analgesia.  Five RCTs have evaluated the use of analgesia for the management of pain 
associated with IUD insertion (Table 1).  Analgesics included the NSAIDs ibuprofen, naproxen 
sodium and ketorolac, the atypical opioid tramadol, and inhaled nitrous oxide.  NSAIDs such as 
naproxen and ibuprofen reduce pain by blocking cyclooxygenase enzyme activity and the 
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formation of exogenous prostaglandin (Bednarek et al., 2015; Chor, Bregand-White, Golobof, 
Harwood, & Cowett, 2012).  Ketorolac is a potent NSAID indicated for short-term moderate 
acute pain with a quicker onset of action compared with oral medications (Ngo, Ward, & Mody, 
2015).  Tramadol is an atypical opioid that inhibits reuptake of serotonin and norepinephrine, as 
well as exhibiting weak μ-agonist activity and is widely used to treat moderate to severe pain 
(Karabayirli, Ayrim, & Muslu, 2012).  Nitrous oxide has analgesic and anxiolytic properties 
thought to be from stimulation of endogenous endorphins, and possibly corticotrophins and 
dopamine, creating euphoria that makes the patient less aware of pain (Rosen, 2002).                                                     
Table 1 
Studies Evaluating Analgesia Used for Pain during IUD Insertion 
Reference n Population Intervention Significance of pain 
reduction effect 
Level of 
evidence 
Bednarek 
et al (2015) 
202 Nulliparous 
and parous 
800 mg ibuprofen 
or placebo orally 
Not significant    
(mean scores 38 vs 
41.5, p = 0.5) 
 
1 
Ngo et al 
(2015) 
67 Nulliparous 
and parous 
30 mg ketorolac 
or normal saline 
placebo 
intramuscularly 
Not significant 
(median pain scores 
3.6 vs 5.2, p = 0.99) 
1 
Singh et al 
(2015) 
80 Nulliparous 50/50 nitrous 
oxide/oxygen or 
oxygen inhaled 
Not significant   
(mean scores 54 vs 
55; p = 0.85) 
I 
Chor et al 
(2012) 
81 Mainly  
parous 
800 mg ibuprofen 
or placebo orally 
Not significant   
(mean scores 3.9 vs 
3.3, p = 0.91) 
 
1 
Karabayirli 
et al (2012) 
103 Parous 50 mg tramadol or 
550 mg naproxen 
sodium  
or placebo orally 
Significant reduction 
in mean pain scores 
with tramadol vs 
naproxen sodium 
(2.31 vs 2.94, p = 
0.003) and with 
naproxen vs placebo 
(2.9 vs 4.8, p = 0.001) 
 
I 
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 Ibuprofen.  In the first RCT, 202 women received either 800 mg ibuprofen or placebo 30 
to 40 minutes prior to IUD insertion (Bednarek et al., 2015).  Ibuprofen had no significant effect 
on patient-reported pain compared with placebo.  Parity was a significant predictor of pain.  The 
subgroup of nulliparous women experienced approximately twice as much pain compared with 
multiparous women, but ibuprofen had no clinically relevant impact on the level of pain 
compared with placebo.   
The second RCT randomized 81 women to receive either 800 mg ibuprofen or placebo 45 
minutes before insertion of an IUD (Chor et al., 2012).  Consistent with the above trial that failed 
to find a difference in pain at the time of IUD insertion between women receiving ibuprofen or 
placebo, prophylactic use of ibuprofen had no significant impact on mean scores of pain.  Mean 
pain scores in both the placebo and ibuprofen study groups indicated a need for managing pain 
during the insertion procedure. 
Ketorolac.  The third RCT evaluated pain control of intramuscular ketorolac 30 mg 
compared with placebo saline solution injection prior to IUD insertion in 67 women (Ngo et al., 
2015).  Although there was not a clinically significant difference between pain scores in the 
placebo compared to the ketorolac group during IUD insertion, there was a decrease in pain 
scores at five and fifteen minutes.  The maximal effect of ketorolac is at one to two hours; 
however, the study was done at 30 minutes.  The majority of participants felt pain from the 
injection was “not as bad” as pain from IUD placement (71% compared with 81%); however, 
20% reported injection site pain was "as bad" as IUD placement.  Median pain scores were 
higher in the nulliparous subgroup compared with multiparous subgroup.  
Nitrous oxide.  One RCT evaluated a fixed blend of 50% nitrous oxide with 50% oxygen 
versus 100% oxygen as placebo inhaled through a mask during IUD insertion in 80 nulliparous 
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women (Singh et al., 2015).  Although pain scores at the time of IUD insertion were slightly 
lower in the nitrous oxide group than in the oxygen group, the difference was not significant.  
However, significantly more women in the nitrous oxide group were more satisfied with their 
pain management, suggesting the usefulness of self-administered nitrous oxide for its anxiolytic 
proeprties.  In the United Kingdom, Sewell and Vincent (2015) have been offering nitrous oxide 
for reducing the pain of IUD insertion and have had a positive response; the authors plan to 
publish results of the trial.  
Tramadol versus naproxen sodium.  In the fifth RCT, 103 women received 50 mg of 
tramadol, 550 mg naproxen sodium, or placebo one hour before IUD insertion (Karabayirli et al., 
2012).  Tramadol demonstrated superior analgesia over naproxen and placebo with pain scores in 
the tramadol group significantly lower than in the naproxen group.  Naproxen sodium was also 
associated with a significant reduction in pain compared with placebo.  Although tramadol mean 
scores were significantly lower when compared with the naproxen group, this difference may not 
be clinically significant as the pain score in both groups were similar.   
 Anesthesia.  The use of local anesthesia in the management of pain for IUD insertion has 
been evaluated in eleven studies (Table 2).  The studies included the use of lidocaine in a number 
of formulations: gel, cream, spray, and injection; with differing techniques of administration: 
topical, intracervical and paracervical.  Lidocaine has a rapid onset of around two minutes or less 
and duration of action of 30 to 60 minutes, but is liable to vary among application sites 
(Tornblom-Paulander et al., 2015).  Allowing adequate time to elapse between the administration 
of lidocaine and IUD insertion is necessary for it to take effect (Tornblom-Paulander et al., 
2015).                                   
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Table 2                                                                                                                                                     
Studies Evaluating Anesthetics for Managing Pain during IUD Insertion 
Author n Population Interventions Significance of pain 
reduction effect 
Level of 
evidence 
Aksoy et al. 
(2015) 
 
200 Parous 10% lidocaine or 
isotonic saline spray 
3 mins prior 
Significant                 
(mean scores 1.01 vs. 
3.23; p < 0.001) 
I 
Tavakolian et 
al. (2015) 
92 Parous Lidocaine-prilocaine 
EMLA or placebo 
cream 7 mins prior 
Significant             
(mean scores 2.65 vs. 
4.61; p < 0.001) 
I 
Tornblom-
Paulander et 
al. (2015) 
218 Parous and 
nulliparous 
Lidocaine 4% or  
placebo gel  
5 mins prior 
Significant                   
(28.3 vs. 44.2; p < 
0.001)  
I 
Castro et al. 
(2014) 
100 Nulliparous  2% lidocaine injected 
5 minutes prior or 
400 mg or ibuprofen 
orally one hr prior  
Not significant (effect 
size < 10%) but showed 
risk of moderate/severe 
pain reduced by 40% 
I 
Allen, Raker, 
& Goyal 
(2013) 
145 Parous and 
nulliparous 
2% lidocaine or 
placebo gel 3 mins 
prior 
Not significant               
(mean scores 35.2 vs. 
36.7; p = .8) 
I 
Cirik et al. 
(2013) 
95 Mostly 
parous 
1% lidocaine or 0.9% 
NaCl paracervical 
block or no analgesia 
Significant            
(median pain 2 vs. 6. vs 
6; p < .001) 
I 
Nelson & 
Fong (2013) 
40 Parous and 
nulliparous 
2% lidocaine or 
normal saline infused 
into endometrial 
cavity 3 minutes prior 
Not significant             
(mean scores 3.0 vs. 3.7; 
p = .40) 
I 
Maguire et al. 
(2012) 
200 Parous and 
nulliparous 
2% lidocaine or 
placebo gel for 1 min 
Not significant               
(mean scores 50.9 vs. 
51.0; p = .98) 
I 
McNicholas 
et al. (2012) 
199 Parous and 
nulliparous 
2% lidocaine or 
placebo gel 
Not significant             
(median pain score 5 vs. 
6; p = .20) 
I 
Mody et al. 
(2012) 
50 Parous and 
nulliparous 
1% lidocaine 
paracervical  or no 
anesthesia 
Not significant          
(median score 24.0 vs. 
62.0; p = .09) 
I 
Mohammad-
Alizadeh-
Charandabi et 
al. (2012) 
96  2% lidocaine or 
placebo gel or no 
intervention 1 min 
prior 
Not significant            
(mean scores 3.4 vs. 3.4 
vs. 3.7) 
I 
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Lidocaine topical gel. The application of lidocaine topical gel before IUD insertion has 
been evaluated in five RCTs.  Four trials compared 2% lidocaine gel versus placebo; one trial 
included a group with no intervention.  Allen et al. (2013) applied gel at the anterior lip of the 
cervix and into the cervical canal.  McNicholas et al. (2012) applied gel to the ectocervix as well 
as via angiocatheter into the endocervical canal three minutes prior to application of the 
tenaculum.  Tornbloom-Paulander (2015) applied gel on the surface of the cervix, into the 
cervical canal, and also into the uterine cavity and for five minutes prior to IUD insertion.  
Maguire et al. (2012) applied 2% lidocaine gel or placebo gel soaked onto a cotton swab and 
inserted into the cervix for one minute.  In the fourth trial 2% lidocaine gel was used 
intracervically and on the outer part of the cervix where the tenaculum is placed, and was 
compared to placebo as well with no intervention (Mohammad-Alizadeh-Charandabi et al., 
2012).  
Pain during IUD insertion did not differ significantly in all the trials.  Lidocaine gel did 
not reduce pain, even among nulliparous women (Allen et al., 2013; Maguire et al., 2012); 
however, McNicholas et al. (2012) reported significantly different insertional pain scores 
between nulliparous and multiparous women regardless of the intervention.  Despite the finding 
that nulliparous women had significantly higher pain scores, reported pain was not different for 
nulliparous women randomized to intracervical lidocaine (McNicholas et al., 2012).  Lidocaine 
treatment was associated with a decrease in pain in patients with severe dysmenorrhea (p = .04) 
(Allen et al., 2013).  
A fifth trial examined use of 8.5 mL of a short-acting  4% lidocaine gel on the cervix, in 
the cervical canal, and into the uterine cavity five minutes before IUD insertion; all participants 
were nulliparous (Tornblom-Paulander et al., 2015).  Mean pain scores were significantly lower 
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in the lidocaine group versus the placebo group, representing a 36% reduction in maximum pain. 
The authors noted that a significantly higher percentage in the lidocaine group was essentially 
pain-free, and a significantly lower percentage had moderate to severe pain.  This study was a 
double-blind, phase -II study with sufficient statistical power to demonstrate the efficacy of 
lidocaine versus placebo, and included as many as 15 providers across three centers, increasing 
the likelihood of results being representative for clinical practice.  
Lidocaine/prilocaine topical cream.  One study evaluated euteric mixture of local 
anesthetics (EMLA) cream, consisting of 2.5% lidocaine and 2.5% prilocaine in 92 women as 
analgesia for IUD insertion (Tavakolian, Doulabi, Baghban, Mortazavi, & Ghorbani, 2015).  
Investigators applied 5 grams to the cervix using a cotton swab seven minutes prior to IUD 
insertion.  Participants in the EMLA group had significantly reduced pain during IUD insertion.  
Lidocaine infusion or spray.  Two trials compared a different application method by 
administering lidocaine versus normal saline as a spray or an infusion.  In the first RCT 
investigators used four pumps of 10% lidocaine spray or placebo in 200 parous women three 
minutes before IUD insertion (Aksoy, Aksoy, Ozyurt, Acmaz, & Babayigit, 2015).  A 
significantly lower score for overall pain during IUD insertion was found in the treatment group 
compared to controls, and no systemic effects were observed with the 10% lidocaine spray.  In 
the second RCT, a pilot study (n = 40), Nelson and Fong (2013) infused 2% lidocaine or placebo 
using a Pipet Curet endometrial aspirator into the lower third, middle, and top of the uterine 
cavity.  Mean pain scores did not differ significantly between the lidocaine and the normal saline 
group, even in the eleven women who took NSAIDs before insertion. 
Lidocaine block.  Three trials injected lidocaine compared to placebo, no intervention, or 
ibuprofen orally. Two studies compared paracervical block of 1% lidocaine to no intervention as 
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control (Cirik, Taskin, Tuglu, Ortac, & Dai, 2013; Mody et al., 2012) or to saline as placebo 
(Cirik et al., 2013). IUD insertion occurred three minutes before (Mody et al., 2012), or five 
minutes before IUD insertion (Cirik et al., 2013).  Although Mody et al. (2012) found a 
statistically significant decrease in pain during tenaculum placement, median pain scores in the 
paracervical lidocaine group were lower but they were not statistically significant.  In the second 
trial study, median pain scores were significantly lower in the lidocaine paracervical group 
compared with saline placebo and with no intervention during IUD insertion (Cirik et al., 2013).  
The third trial compared an intracervical block of 2% lidocaine five minutes before IUD 
insertion, versus 400 mg ibuprofen orally one hour prior to the procedure in 100 women who 
were nulliparous or without previous vaginal delivery (Castro et al., 2014).  Pain did not differ 
between the two groups, although intracervical anesthesia reduced moderate to severe pain by 
40% but without statistical significance.  
Cervical priming.  The impact of cervical priming on pain associated with IUD insertion 
has been evaluated in eight RCTs with misoprostol, a prostaglanding analog, and two pilot 
studies examined the nitric oxide donors, nitroglycerin and nitroprusside (Table 3).  Cervical 
priming refers to dilating or softening of the cervix prior to IUD placement which may reduce 
pain during the insertion procedure.  Misoprostol acts on the cellular matrix of the cervix causing 
dissolution of collagen fibers and increasing the amount of fluid in the stroma resulting in 
cervical effacement (Scavuzzi et al., 2013).  Route for administration of misoprostol included 
oral (buccal and sublingual) and vaginal; however, time of administration prior to the IUD 
insertion procedure varied.  Nitroprusside and nitroglycerine are smooth muscle relaxants with 
the potential to induce cervical ripening without causing uterine cramping, the most significant 
side effect of misoprostol (Micks et al., 2014).            
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Table 3                                                                                                                                                    
Published Studies about Cervical Priming to Facilitate IUD Insertion 
Author n Population Interventions Significance of pain 
reduction effect 
Level of 
evidence 
Bednarek et 
al. (2015) 
24 Nulliparous 10 mg nitroprusside 
or placebo gel 
(intracervical) 
immediately prior  
Not significant  
(61 vs 74, p = 0.18) 
Pilot study 
Micks et al.  
(2014) 
24 Mostly 
nulliparous 
0.5 mg nitroglycerin 
or placebo gel 
(vaginal) 30 min 
prior  
Not significant  
(57.4 vs 55, p = 
0.82) 
Pilot study 
Esprey et al. 
(2014) 
85 Nulliparous 400 mcg misoprostol 
or placebo (orally)  
2 - 8h prior 
Not significant  
(58 vs 59, p = 0.94) 
1 
Lathrop et al. 
(2013) 
71 Nulliparous 400 mcg misoprostol 
or placebo (orally)  
2 - 4 hours prior 
Significant but for 
increased pain  
(46.5 vs 35.1, p = 
0.04) 
1 
Scavuzzi et 
al. (2013) 
179 Nulliparous 400 mcg misoprostol 
or placebo (vaginal) 4 
hours prior 
Significant                
(44% reduction 
misoprostol group, p 
= 0.00004) 
1 
Ibrahim & 
Ahmed 
(2013) 
200 Parous 400 mcg misoprostol 
(sublingual) and 100 
mg diclofenac (oral) 
vs diclofenac 1 hour 
prior 
Not significant  
(70 vs 65, p = 0.8) 
1 
Swenson et 
al. (2012) 
105 Nulliparous 400 mcg misoprostol 
or placebo (vaginal) 
3-4 hours prior 
Not significant  
(58.4 vs 56.9, p =  
0.74) 
1 
Edelman et 
al. (2011) 
35 Nulliparous 400 mcg misoprostol 
or placebo (orally) 90 
min prior 
Not significant  
(65 vs 55, p = 0.83) 
1 
Dijkhuizen et 
al. (2010) 
270 Nulliparous 
and parous 
400 mcg misoprostol 
or placebo (vaginal) 
3hours prior 
Not significant  
(46 vs 40, p = 0.14) 
1 
Heikinheimo 
et al. (2010) 
89 Mostly 
parous 
400 mcg misoprostol 
or placebo 
(sublingual) 3hours 
prior 
Not significant 
(misoprostol group 
vs placebo did not 
report less pain) 
1 
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Nitroprusside and Nitroglycerin.  The first randomized, double-blinded, placebo-
controlled pilot study compared 10 mg nitroprusside compounded into a 1% aqueous gel with an 
identical-appearing placebo gel intracervically in 24 nulliparous women immediately before IUD 
insertion (Bednarek et al., 2015).  The second pilot study compared 0.5 mg nitroglycerin 
ointment and identical placebo ointment applied vaginally at the posterior fornix 30 to 45 
minutes prior to IUD insertion in 24 nulliparous women (Micks et al., 2014).  Subjects were 
given the option of taking ibuprofen prior to the procedure.  In both pilot studies, there were no 
statistically significant differences between mean pain scores, ease of insertion, or reports of side 
effects in treatment groups.  
Vaginal misoprostol.  Three RCTs evaluated misoprostol inserted vaginally for cervical 
priming prior to IUD insertion.  In the first trial, 400 mcg of misoprostol vaginally three hours 
before IUD insertion versus placebo was evaluated in 199 nulliparous and multiparous women 
(Dijkhuizen et al., 2010).  No difference in pain scores between the groups was found; however, 
there was a non-significant trend towards increased pain in the misoprostol group, and among the 
subgroup of nulliparous women pain scores and healthcare provider difficulty of insertion were 
higher.  There was a statistically significant increase in side effects experienced by the 
misoprostol group compared with the placebo group, most commonly abdominal cramping.  
Misoprostol 400 mcg inserted vaginally was also compared to placebo in the second trial, 
but it was placed four hours prior to the procedure (n = 179), and only included nulliparous 
women (Scavuzzi, Souza, Costa, & Amorim, 2013).  In this study, the misoprostol group had a 
significant 44% reduction in moderate-to-severe pain compared with the placebo group.  
Although less subjective healthcare provider difficulty in inserting the IUD was reported, there 
was a greater incidence of cramps.  
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The third trial randomized participants to self-administer either 400 mcg of misoprostol 
or placebo, and they were instructed to insert it vaginally or orally three to four hours before the 
IUD appointment (Swenson et al., 2012).  Data was analyzed excluding oral administration as 
94% had chosen to insert it vaginally.  No significant difference in pain was found during IUD 
insertion, nor was healthcare provider ease of insertion significantly different between the two 
groups.  Also, pain was significantly higher before IUD insertion in the misoprostol group.  
Oral misoprostol.  The impact of cervical priming with oral administration of 
misoprostol has been evaluated in five placebo-controlled RCTs.  In the first trial 35 nulliparous 
women took misoprostol 400 mcg or placebo orally 90 minutes prior to IUD insertion (Edelman 
et al., 2011).  The procedure also included local anesthesia at the tenaculum site; either 
benzocaine spray or 1% lidocaine injection.  No significant difference in pain or provider ease of 
insertion was found between the groups.  
Esprey et al. (2014) also compared 400 mcg oral misoprostol or placebo in a larger 
population of nulliparous women (n = 85), but taken two to eight hours before IUD insertion.  
Highest level of pain was similar between both groups, and providers did not indicate any 
difference in ease of IUD insertion.  Pain scores in the study confirmed that nulliparous women 
experience considerable pain during IUD insertion.  
The third study conducted in nulliparous women (n = 71) evaluating 400 mcg oral 
misoprostol was conducted by Lathrop et al. (2013).  In this study, misoprostol or placebo was 
taken two to four hours prior to IUD procedure, and those in the misoprostol group reported 
significantly more pain than those in the placebo group.  Nulliparous women reported an 
approximately two-fold increase in pain compared to multiparous women.  Provider perception 
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of ease of insertion was not significantly different, and the addition of misoprostol did not 
decrease the need for additional measures such as cervical dilation.    
Two RCTS were conducted in mostly parous women to evaluate oral administration of 
misoprostol for cervical priming.  The first aimed to compare sublingual misoprostol 400 mcg 
and placebo three hours prior to IUD insertion in 89 mostly multiparous women who were 
having an IUD removed followed by immediate insertion of a new IUD (Heikinheimo et al., 
2010).  Sublingual misoprostol did not have a significant effect on the ease of insertion.  Overall 
pain experience did not differ between the two groups, yet severe pain and a significant increase 
in side effects was reported in the misoprostol group.  The second RCT evaluating sublingual 
misoprostol was conducted in 200 parous women delivered by cesarean section and included 
comparison of 400 mcg misoprostol and 100 mg diclofenac with 100 mg diclofenac orally one 
hour prior to IUD insertion (Ibrahim & Ahmed, 2013).  Adding misoprostol to diclofenac prior 
to IUD insertion did not result in significant differences in patient-reported pain experienced, and 
ease of insertion was not significantly different between the two groups.  
 Non-pharmacological Interventions.  In the absence of clear evidence supporting 
pharmacological interventions, the scope of the appraisal was expanded to include additional 
strategies used in clinical practice.  Additional strategies identified included delayed bladder 
emptying, aromatherapy, pre-placement counseling, and distraction.  Bladder distention causes 
the uterine axis to become more aligned with the cervical canal which may facilitate easier 
insertion of an IUD and reduce pain (Cameron, Glassier, Cooper, & Johnstone, 2013).  
Aromatherapy with lavender oil has anxiolytic properties which may lead to reduced pain 
(Shahnazi et al., 2012).  Psychological preparation before placement may reduce the perception 
of pain by reducing uncertainty, and information and reassurance of what to expect may lead to a 
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higher level of pain tolerance (Bahamondes, Mansour, Fiala, Kaunitz, & Gemzell-Danielsson, 
2014).  During the insertion procedure, distraction provided verbally by the provider or a support 
person, or from the warmth of a heating pad may reduce the perception of pain (Gemzell-
Danielsson et al., 2013). 
Delayed bladder emptying.  One study proposed use of delayed bladder emptying for 
management of pain during IUD insertion (Cameron, Glassier, Cooper, & Johnstone, 2013).  To 
determine if IUD insertion is easier in women who have a full bladder at the time of insertion, 
200 women with a pre-filled bladder were randomized to either delayed emptying after IUD 
insertion or immediate emptying before IUD insertion.  There was no significant decrease in pain 
scores between the two groups.  
Aromatherapy.  Shahnazi et al. (2012) randomized 106 women to inhale ten drops of 
lavender scent or placebo 30 minutes before IUD insertion.  Pain scores after intervention did not 
show a significant difference between the lavender scent and the placebo groups.  However, 
mean differences of anxiety in both groups was statistically significant showing a positive effect 
of aromatherapy as complementary treatment. 
Pre-placement counseling and distraction.  Non-pharmacological interventions aimed at 
reducing anxiety before and during the IUD placement may be effective at decreasing pain; 
however, no studies on these approaches have been published to date.  Recently published 
consensus recommendations based on expert opinion stated that non-pharmacological pain 
management strategies should be used by the provider (Bahamondes et al., 2014).  These 
interventions included pre-placement counseling and the use of distraction during the insertion 
procedure.  The provision of realistic information on what to expect during the procedure, 
discussion of the variable level of pain women experience, and explanation on the measures that 
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will be taken to minimize discomfort should occur prior to IUD placement.  Other supportive 
non-pharmacological measures aimed at distraction during the procedure to reduce the 
perception of pain included the woman concentrating on holding a heating pad suprapubically.  
A technique called 'vocal local' through conversational distraction by the provider or a support 
person was one of the most effective ways of decreasing anxiety and pain.  As this article is 
based on expert opinion it was excluded from the critical appraisal.  
Implications for Practice 
Analgesia.  Oral NSAIDs such as naproxen sodium and ibuprofen are widely available; 
and inexpensive methods of analgesia used successfully in many clinical settings.  They require 
one to two hours to have adequate effect as peak serum levels are attained at one to two hours 
after administration, with analgesia lasting eight to twelve hours.  It is possible that pain may be 
decreased in the hours after IUD placement.  Ketorolac is relatively inexpensive, can be stocked 
in clinics, and has a wait time of 30 minutes compared with one hour for oral analgesics, with 
analgesia lasting four to six hours.  Logistical considerations might make routine use of ketorolac 
unrealistic in many clinic settings due to the need for intramuscular injection and a healthcare 
provider available to administer it, as well as an in-clinic wait time of 30 minutes.  Analgesic 
effects of tramadol (an atypical opioid prescription medication) begin within one hour, reach 
peak concentration after two to three hours and have a duration of action of four to six hours.  It 
has superior analgesia over NSAIDs and unlike other opioids, has no effects on the respiratory or 
cardiovascular systems.  Nitrous oxide might not reduce IUD insertion pain, but was found to 
increase satisfaction with pain management during the procedure (Singh et al., 2015).  
Availability, access, and training for nitrous oxide would need to be addressed in order to offer 
this form of analgesia for IUD insertion.                                                                                          
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 Anesthesia.  Studies confirmed a lack of efficacy for lidocaine 2% gel in reducing pain 
with IUD insertion.  Physiologically, this intervention would require allowing enough time 
before IUD insertion based on the pharmacologic properties of the gel, while considering a 
reasonable time to leave the speculum in place.  With adequate time a reduction in pain may 
occur; however, this is also dependent on how long a patient will tolerate having a speculum in 
place or having multiple speculum insertions if it is removed after anesthetic administration then 
replaced for IUD insertion.   
The use of a 20 gauge angiocatheter to introduce the 2% lidocaine intracervically 
provided an innovative delivery mechanism allowing the gel to be placed the length of the 
cervical canal, but the use of 2% lidocaine did not reduce pain (McNicholas et al., 2012).  
Administration of a short-acting 4% viscous lidocaine solution five minutes before IUD insertion 
may be a viable anesthetic for managing IUD insertion-related pain without any apparent safety 
concerns (Tornblom-Paulander et al., 2015).  The viscosity of the formulation of this lidocaine 
4% solution minimizes leakage so administration of the anesthetic to the intended tissues is 
prolonged, leading to reduced pain.  The other local anesthetic application, EMLA 5% cream as 
a topical anesthetic on the cervix before IUD insertion reduced pain after a seven minute wait 
time (Tavakolian et al., 2015).   
Lidocaine 10% spray is a simple and convenient topical anesthetic with minimal side 
effects.  The one study demonstrated a significant reduction in overall procedural pain in the 
lidocaine treatment group showing it can be effective in reducing pain scores during IUD 
insertion (Aksoy et al., 2015).  Although a pilot study, Nelson and Fong (2013) did not 
demonstrate any advantage for infusing small amounts of lidocaine into the endometrial cavity to 
reduce pain associated with IUD insertion.  One trial demonstrated lower pain scores after 
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lidocaine injection (Cirik et al., 2013); however, paracervical anesthesia with lidocaine did not 
significantly reduce pain in the other two trials (Castro et al., 2014; Mody et al., 2012).  Also, 
participants reported high levels of pain with paracervical block administration which may 
dissuade providers from this method even if it helps decrease pain during IUD insertion.  
 Cervical priming.  Nitroprusside or nitroglycerin are inexpensive, stable at room 
temperature, readily available, and have a well-established safety profile with application to 
mucosal surfaces, but results of the two pilot studies do not support benefit prior to IUD insertion 
(Bednarek et al., 2013; Micks et al., 2014).  Pain scores with IUD insertion are highly variable 
among women, so a large number of subjects may yield very different results.  However, it is 
unlikely that larger studies would demonstrate benefit as the maximum difference in mean pain 
scores was less than the 15- to 20- mm difference on a 100-mm visual analog score considered to 
be clinically significant.  
Misoprostol has a short half-life, is stable at room temperature, inexpensive, and the dose 
can be adjusted.  Several aspects of cervical ripening regimens for IUD insertion remain unclear: 
the minimal dose, timing of administration, and optimal route to obtain the necessary degree of 
cervical softening before IUD insertion.  No study has established a standard on these variables.   
Minimal dilation is needed for IUD insertion; therefore, it is likely that the 400 mcg doses 
administered in the included studies was too high, causing unnecessarily high rates of side 
effects, mainly pain from uterine cramping.  The time for misoprostol to exert its effect on the 
cervical tissue varies according to the route of administration.  When misoprostol is used orally 
or sublingually, peak concentration occurs in less than 30 minutes, and decreases rapidly 
thereafter.  However, when the vaginal route is used, peak plasma concentration occurs after one 
hour, there is a gradual decrease with levels remaining high for at least six hours, and at 
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substantially higher levels than when administered orally.  Also, when administered by the 
vaginal route, side effects of misoprostol are milder and more self-limiting than when taken 
orally (Scavuzzi et al., 2013).   
In only one of the eight trials, the use of misoprostol 400 mcg inserted vaginally by the 
provider four hours prior to insertion of the IUD was shown to significantly reduce moderate-to-
severe pain, and increase ease of insertion in nulligravidas (Scavuzzi et al., 2013).  None of the 
other RCTs demonstrated a significant reduction in patient reported pain with the use of 
misoprostol for cervical priming prior to IUD insertion.  Although there was variation between 
the studies in route (vaginal or oral) and timing (90 minutes to four hours) of misoprostol 
administration, the dose (400 mcg) was the same in each study and the overall findings were 
consistent.  Furthermore, in all eight RCTs, premedication with misoprostol was associated with 
an increase in side effects.  Subjects randomized to misoprostol experienced significantly more 
nausea and uterine cramping (Gemzell-Danielsson et al., 2013).   
The studies described covered a wide variety of patients, including nulliparous and 
multiparas, and women who were having an IUD removed and replaced.  Only one RCT 
demonstrated a clinical benefit to the use of misoprostol for cervical preparation before IUD 
insertion (Scavuzzi et al., 2013).  The authors of the other seven of the RCTs concluded that 
women should not be routinely premedicated with misoprostol before IUD insertion because the 
potential harms outweigh the possible benefits (Dijkhuizen et al., 2010; Edelman et al., 2011; 
Esprey et al., 2014; Heikinheimo et al., 2010; Ibrahim & Ahmed, 2013; Lathrop, Haddad, 
McWhorter, & Goedken, 2013; Swenson, Turok, Ward, Jacobson, & Dermish, 2012).  
Only one study to date specifically addresses the issue of patients who have previously 
experienced a failed IUD insertion attempt, but was not included in the critical appraisal as it did 
MANAGEMENT OF PAIN DURING INTRAUTERINE DEVICE 33 
 
not discuss pain (Bahamondes, Espejo-Arce, & Bahamondes, 2015).  Researchers determined 
pretreatment with intravaginal administration of 200 mcg of misoprostol after IUD insertion 
failure then and four hours before the second attempt of IUD placement was significantly better 
than placebo at facilitating the insertion of an IUD.  Further studies are needed to determine if 
the benefit of using misoprostol in this specific clinical setting outweighs the risk of side effects. 
 Non-pharmacological interventions.  Evidence for non-pharmacological strategies for 
the management of pain during IUD insertion was limited.  Cameron et al (2013) found that the 
presence of urine in the bladder does not facilitate easier insertion of an IUD or reduce pain.  
When lavender was inhaled 30 minutes prior to IUD insertion, pain was not reduced but reduced 
anxiety was demonstrated (Shahnazi et al., 2012).  Anxiety may contribute to higher levels of 
perceived pain during IUD insertion, so reduction of anxiety is a good strategy to manage pain 
during the procedure.  Although no other studies for the non-pharmacological management of 
pain during IUD insertion were identified for critical appraisal, expert consensus by Bahamondes 
et al (2014) is that clinicians should use non-pharmacological pain management strategies.  
These included psychological preparation prior to IUD placement and a support person to 
provide distraction during the procedure.   
Translation into Guidelines 
This project takes an evidence-based approach to provide recommendations for the 
management of pain during IUD insertion.  Evidence was drawn from randomized controlled 
trials which represent the gold standard for determining efficacy and effectiveness.  Although 
this project provides evidence-based recommendations for the management of pain during IUD 
insertion, they are not a substitute for clinical judgment.  Decisions about care must carefully 
consider and incorporate the clinical characteristics and circumstances of each individual patient.  
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Implications for practice are made with an expectation that health professionals will use this 
evidence with consideration of the context, their clinical judgment, and the patient's preference.  
 Analgesia.  There is currently no evidence to recommend routine prophylactic use of 
ibuprofen as none of the studies revealed that it reduces insertion-related pain.  Data from one 
RCT suggests that prophylactic use of tramadol or naproxen sodium may reduce pain on IUD 
insertion (Karabayirli et al., 2012); however, larger follow-up studies are required to confirm 
these findings.  One study supports use of ketorolac, but only for decreasing pain after IUD 
insertion (Ngo et al., 2015).  Nitrous oxide was found to have a rapid onset of action with few 
adverse effects, and improved patient satisfaction with pain management (Singh et al., 2015).   
 Anesthesia.  There is currently no supporting evidence from RCTs to recommend routine 
use of local anesthesia for IUD insertions.  Lidocaine 2% gel showed no effect on pain with all 
the studies confirming its lack of efficacy, although one study suggested it may have beneficial 
effect in women with a history of severe dysmenorrhea (Allen et al., 2013).  Other lidocaine 
formulations may lesson pain during IUD insertion.  These include lidocaine 4% applied on the 
surface of the cervix, in the cervical canal, and into the uterine cavity (Tornblom-Paulander et 
al., 2015); a lidocaine and prilocaine cream on the cervical opening (Tavakolian et al., 2015); 
and 10% spray on the cervical surface (Aksoy et al., 2015).  Wait times between application and 
procedure for these formulations to act ranged from three to seven minutes.  There is limited 
evidence supporting routine use of paracervical anesthesia for IUD insertion; however, injectable 
local anesthesia for lidocaine paracervical block should be on hand for reactive administration 
when complications arise, such as the need for dilation (Bahamondes et al., 2014).   
 Cervical priming.  There is no clear evidence that cervical priming with nitroprusside, 
nitroglycerin, or misoprostol reduces pain during IUD insertion.  No studies define optimal 
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misoprostol regimens and there is a lack of data on the clinical usefulness of cervical priming for 
IUD insertion to reduce pain.  In addition, painful uterine cramping is more likely with the use of 
misoprotol (Gemzell-Danielsson et al., 2013).   
 Non-pharmacological interventions.  The presence or absence of urine in the bladder 
does not facilitate easier insertion of an IUD or reduce pain (Cameron et al., 2013).  
Aromatherapy was found to be effective in decreasing anxiety for IUD insertion and may be 
used as complementary treatment although it may not decrease actual pain (Shahnazi et al., 
2012).  Counseling should be done prior to IUD placement and include realistic information 
about what to expect during the procedure, discussion about the variable level of pain that 
women experience, and explanation of the measures that will be taken to minimize discomfort 
(Bahamondes et al., 2014).  A support person or an assistant to provide distraction during the 
procedure is effective in reducing anxiety and pain (Bahamondes et al., 2014).   
Significance to Advanced Nursing Practice 
The IUD is steadily regaining interest among women seeking a highly effective and long-
acting reversible contraceptive method.  Pain associated with the insertion of an IUD is one 
barrier to intrauterine contraceptive use; therefore, effective strategies for pain management have 
the potential to promote the use of IUDs in women who would otherwise opt out of an IUD 
because of fear of pain at insertion.  It is good practice for advanced nurse practitioners (ANPs) 
to discuss, offer, and use evidence-based interventions for a procedure that may cause pain, such 
as insertion of an IUD.   
ANPs provide frontline care in women's health, including contraception, an essential 
preventive service, and have an important position in addressing unintended pregnancy.  IUDs 
are supported as first-line contraception for women of all ages, including adolescents (Smith & 
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Daly, 2011) and provide an additional contraceptive option for ANPs to offer their patients.  IUD 
use has increased nearly five-fold in the last decade (Finer, Jerman, & Kavanaugh, 2012), and 
56% of the first 2,500 women enrolled in the Contraceptive CHOICE project selected 
intrauterine contraception (Secura, Allsworth, Madden, Mullersman, & Peipert, 2010).  As more 
women are being offered and choosing this method, health care providers need updated 
recommendations for pain control with placement of an IUD. 
Dissemination 
A manuscript will be prepared for submission to the Journal of Advanced Nursing.  This 
journal provides a venue for circulating recommendations for the management of pain during 
IUD insertion as it is an international, peer-reviewed journal dedicated to addressing aspects of 
evidence-based nursing.  An alternative dissemination plan would include a poster presentation 
at the annual Alaska Advanced Nursing Practice conference.  
Summary 
 Twenty nine randomized controlled trials from 2010 to 2015 evaluating interventions 
were critically appraised for managing pain during IUD insertion.  Several interventions did not 
reduce pain; however, a few interventions helped lesson pain.  Naproxen decreased pain among 
parous women and in the first hours afterward in nulliparous women; however, studies showed 
no benefit of ibuprofen.  Tramadol reduced pain in parous women, but only slightly more than 
naproxen sodium.  Lidocaine 4% topical gel in nulliparous women, 10% spray in parous women, 
lidocaine/prilocaine cream, and 1% paracervical block reduced pain.  Misoprostol increased pain 
and cause more side effects.  Inhaled nitrous oxide and aromatheraphy with lavender reduced the 
anxiety contributing to higher levels of perceived pain during IUD insertion.   
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Conclusion 
Research has shown that long-acting reversible contraceptive methods, including IUDs, 
are highly effective, and there has been an increase in the use of this type of contraception.  
Despite the benefits associated with IUDs, one barrier is the fear of pain during the insertion 
process.  Studies emphasized the varying pain women experience with IUD insertion; however, 
no single intervention was shown to consistently reduce the pain associated with IUD placement.  
After critical appraisal of the evidence it can be concluded that use of ibuprofen, lidocaine 2% 
gel, and misoprostol does not reduce pain; however, tramadol, naproxen, lidocaine 4% gel, 
lidocaine 10% spray, lidocaine/prilocaine cream, and lidocaine injectable block may help in 
managing IUD insertion-related pain.  Other interventions highlighted that reduction of anxiety 
is a good strategy to attempt to reduce pain during IUD insertion.  This project contributes to the 
body of literature in support of easing the pain of IUD insertion as part of a comparative analysis 
to assist in the development of guidelines for managing pain during IUD insertion. 
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Appendix A 
 
Evidence-based Management of Pain during Intrauterine Device (IUD) Insertion 
 
 
Figure A - 1                              See back for References* 
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Figure A - 2 
 
 
Management of pain during intrauterine device insertion  
based on empirical evidence* 
Predictors of increased pain:                                                                                                                                    
Age > 30 years                                                                                                                                                          
Nulliparity  or no vaginal delivery                                                                                                                                
Lengthier time since last pregnancy or menses                                                                                                 
Not currently breastfeeding                                                                                                                                     
Higher expected pain                                                                                                                               
Lower self-reported pain tolerance 
                                                                                                                           
                                                                                                                             
 
Non-pharmacological strategies 
                    Pre-placement counseling: what to expect 
                    Distraction during procedure: support person 
                    Lavender aromatherapy: to reduce anxiety 
Analgesia 
Naproxen sodium or tramadol: 
to reduce pain during insertion 
in parous women, and in the 
hours after in nulliparous 
women 
Self-administered nitrous 
oxide:  to reduce anxiety and 
improve patient satisfaction 
with pain management 
 
 
Anesthesia     
Lidocaine 4% gel on cervix, in 
cervical canal, and into                     
uterine cavity   
Lidocaine/prilocaine cream             
on cervix    
Lidocaine 10% spray on cervix 
Wait time 3 to 7 minutes            
after application 
Lidocaine cervical block: if                 
patient requesting pain relief 
experiences severe pain                       
or need for dilation 
 
 
 
Cervical 
priming 
Routine use not 
recommended: 
Likely to increase 
overall pain and 
incidence of            
side effects 
 
If patient still 
desires IUD after 
failed insertion 
due to cervical 
stenosis:  
Consider 
misoprostol 
vaginally 4 hours 
prior to  new 
appointment  
Offer NSAID          
to reduce 
prostaglandin-
mediated side 
effects such as 
uterine cramping 
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Management of Pain during IUD Insertion based on Empirical Evidence* 
 
Non-pharmacological interventions 
 Counseling prior to IUD placement including realistic information about what to expect 
during the procedure, discussion about the variable level of pain that women experience, 
and explanation of the measures that will be taken to minimize discomfort.  
 A support person or an assistant to provide distraction during the procedure to reduce 
anxiety and the perception of pain. 
 Aromatherapy as complementary treatment to decrease anxiety for IUD insertion. 
 
Analgesia 
 There is currently no evidence to recommend routine prophylactic use of ibuprofen. 
 Data supports prophylactic use of tramadol or naproxen sodium to reduce pain.  Although 
tramadol exerted superior analgesia, the difference may not be clinically significant as 
mean pain scores in tramadol and naproxen sodium groups were similar. 
 Nitrous oxide has a rapid onset of action with few adverse effects, and improves patient 
satisfaction with pain management. 
 
Anesthesia 
 If a patient requests pain relief, experiences severe pain, or there is a need for dilation,  
lidocaine cervical block may be injected.  
 Lidocaine 2% gel showed no effect on pain with all studies confirming lack of efficacy. 
 Other lidocaine formulations may lesson pain during IUD insertion: lidocaine 4% applied 
on the surface of the cervix, in the cervical canal, and into the uterine cavity; a lidocaine 
and prilocaine cream on the cervical opening; and 10% spray on the cervical surface.  
 Allowing adequate time to elapse is necessary for them to take effect.Wait times between 
application and IUD insertion ranges from three to seven minutes.  
 
Cervical priming 
 There is no benefit for the routine use of misoprostol for cervical priming. 
 If the patient still desires an IUD after a failed insertion due to cervical stenosis, consider 
rescheduling and self-administration of vaginal misoprostol 4 hours prior to the new 
appointment and offer NSAID to reduce cramping side effects. 
 With vaginal route, peak plasma concentrations occur in 1 hour, and at substantially 
higher levels than when administered orally; side effects are also milder.  
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Appendix B  
 
Permission to Reproduce Star Model of Knowledge Transformation 
 
From: Center for Advancing Clinical Excellence <acestar@uthscsa.edu> 
Date: Mon, Aug 10, 2015 at 4:22 PM 
Subject: RE: permission to reproduce ACE figure 
To: Debra Booysen <dcbooysen@alaska.edu> 
 
Ms. Booysen, 
  
Dr. Stevens has reviewed your request, and you may use it under the fair-use rule, but you will 
need to give written credit. However, if you are re-publishing the copyrighted material, specific 
permission is required. Dr. Stevens is the copyright holder and grants you permission to include the 
model image and a paraphrased description of the model. The image must be accompanied with this 
phrase: "Copyrighted material (Stevens, 2012). Reproduced with expressed permission" and the 
bibliographic reference include:  Stevens, K. R. (2012). ACE Star Model of EBP: Knowledge 
Transformation. The University of Texas Health Science Center San Antonio. 
  
Just recently, Dr. Stevens has updated the name of the ACE Star Model to the    Stevens Star 
Model of Knowledge Transformation    so she has asked me to share this information with you.  You 
may have to update the bibliographic reference to reflect this change.  If you have any questions, you 
may contact Dr. Stevens at stevensk@uthscsa.edu    
  
On another note, our Center is also involved with the Improvement Science Research Network 
(ISRN). The ISRN's work is to advance the emerging field of improvement science. Our mission is to 
advance the scientific foundation for quality improvement, safety and efficiency through 
transdisciplinary research addressing healthcare systems, patient centeredness, and integration of 
evidence into practice. It provides a laboratory to greatly enhance feasibility and generalizability of NIH ( 
National Institutes of Health) proposals in improvement science.  Additionally, it provides an 
infrastructure for a national program of research to test quality improvement interventions. The ISRN is 
comprised of national members, the Network Coordinating Center and a Steering Council.  Research 
Priorities were adopted for the ISRN as the best thinking to date about the direction that should be 
taken in improvement science.  Please visit our ISRN website at www.ISRN.net    for further details. 
  
Thank you for your interest in improving care and patient outcomes.    
  
  
Joan Feller 
Administrative Assistant Associate 
Center for Advancing Clinical Excellence (ACE) 
UT Health Science Center San Antonio 
7703 Floyd Curl Drive, MC 7949 
San Antonio, TX 78229-3900 
Phone: (210) 567-1480 
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Appendix C 
IRB Exempt Approval I  
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Appendix D 
 
Critical Appraisal Table 
 
APA citation 
 
Critical Appraisal Table 
 
Method 
 
Description of design and how study was carried out   
 
 
Population 
 
Number and characteristics of patients e.g. nulliparous 
 
 
Variables 
(Interventions) 
Variables or type of intervention e.g. ibuprofen, lidocaine 
 
 
Measurement 
(Method of 
evaluation of pain) 
Scale used to measure outcome variable e.g. VAS  
Data Analysis 
(Significance of pain 
reduction effect) 
Statistics used to answer clinical question 
Findings Statistical or qualitative findings for each statistical test  
 
 
Appraisal: 
Worth to Practice 
Feasibility of use in ANP practice 
 
 
Level of 
Evidence 
According to John Hopkins hierarchy of evidence table 
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Appendix E 
Johns Hopkins Hierarchy of Evidence Table 
 
                Strength of the Evidence 
Level I Experimental study/randomized controlled trial (RCT) or meta-analysis of  
RCT 
Level II Quasi-experimental study 
Level III Non-experimental study, qualitative study, or meta-synthesis 
Level IV Opinion of nationally recognized experts based on research evidence or expert  
consensus panel (systematic review, clinical practice guidelines) 
Level V Opinion of individual expert based on non-research evidence. (includes case  
studies, literature review, organizational experience e.g., quality improvement  
and financial data, clinical expertise, or personal experience) 
Note. Newhouse, Dearholt, Poe, Pugh, & White (2005). The Johns Hopkins Evidence-based  
Practice Rating Scale.   
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Appendix F 
 
Critical Appraisal Table of Included Studies 
 
Citation Aksoy, H., Aksoy, U., Ozyurt, S., Acmaz, G., & Babayigit, M. (2015).  
Lidocaine 10% spray to the cervix reduces pain during intrauterine  
device insertion: A double-blind randomised controlled trial. Journal of  
Family Planning and Reproductive Health Care, 1-5. 
Design/Method Randomized, double-blind, placebo-controlled trial. Kayseri Education  
and Research Hospital tertiary family planning clinic, Turkey. 
Population 200 parous women aged 19 - 49 years. 
Variables/Intervention Four pumps of 10% lidocaine spray or four pumps of isotonic saline  
solution spray (three puffs to cervical surface and one puff specifically  
towards external cervical os) and waited three minutes before insertion. 
Measurement Patient rated pain on a standard continuous 10-cm VAS, from 0 cm (no  
pain) to 10 cm (worst pain ever).  
Data analysis 190 subjects needed to detect clinically significant difference when  
assuming a power of 80% to detect the primary hypothesis and a type 1  
error of 0.05. Normality tested using Shapiro-Wilk test. Variance  
homogeneity tested using Levene's test. Values expressed as mean±SD  
or median. Parametric comparisons using Mann-Whitney U-test.  
Statistical significance recognized when p < 0.05. Analyses made by  
G*Power 3.1.7 (Heinrich Heine University, Germany).  
Findings Significantly lower score for overall pain during IUD insertion found in  
treatment group compared to controls (p < 0.001). Control group  
experienced greater pain than those in treatment group (mean scores  
3.23 ± 1.60 vs 1.01 ± 1.20, p < 0.001).  The frequency of VAS ≥ 4 was  
statistically significant (41% in controls vs 6% in treatment group, p <  
0.001). No systemic side effects observed with 10% lidocaine spray. 
Worth to practice Lidocaine spray is a simple and convenient topical anesthetic with  
minimal adverse effects. Study demonstrated a significant reduction in  
overall procedural pain in lidocaine treatment group compared with  
placebo group; shows it can be effective in reducing pain scores during  
IUD insertion.  
Level of evidence I 
Notes  All insertions performed by same gynecologist and team. No  
nulliparous women. 
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Citation Allen, R. H., Raker, C., & Goyal, V. (2013). Higher dose cervical 2%  
lidocaine gel for IUD insertion: A randomized controlled trial.  
Contraception, 88, 730-736. 
Design/Method Randomized, double-blind, placebo-controlled trial. University  
obstetrics and gynecology practice, Providence, RI. 
Population 145 nullip and parous women 18 to 49 years. 
Variables/Intervention 3 mL of 2% lidocaine gel or placebo gel (KY Jelly) in a 1:1 ratio at the  
anterior lip of the cervix and 3 mL in the cervical canal for 3 min. 
Measurement Participants rated pain on 0- to 100-mm visual analog scale (VAS).     
Data analysis 144 subjects needed assuming an alpha of 0.05, 80% power and a SD of  
32 mm to detect a 15-mm mean difference and to minimize a potential  
Type II error. Chi-square or Fisher's Exact test for categorical variables.  
Wilcoxon rank sum or t test for continuous variables.  Association of  
lidocaine gel with pain on IUD insertion examined by multiple linear  
regression. Interactions between treatment group and predictors  
evaluated by an overall F test, and Dunnett method. All p values two- 
tailed, with p < 0.5 statistically significant. SAS version 9.2. 
Findings Pain with IUD insertion was no different with a mean pain score of 35.2  
(median: 34) in the lidocaine group and 36.7 (median: 36) in the placebo  
group (p = .8). No difference even in nulliparous. Lidocaine treatment  
was associated with a 31.8 point (95% CI: 0.9 - 62.8, p = .04) decrease  
in pain in patients with severe dysmenorrhea. No difference between  
groups in procedure difficulty as rated by provider. No participants  
reported any systemic lidocaine side effects.  
Worth to practice Confirms lack of efficacy. Lidocaine gel did not reduce pain, even  
among nulliparous women. Study showed it may have a beneficial  
effect in women with a history of severe to very severe dysmenorrhea.  
Level of evidence I 
Notes  Provided useful information on predictors of pain: increased pain  
associated with  nulliparity, interval IUD insertion and history of  
dysmenorrhea. 37 different providers inserted IUDs. 
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Citation Bednarek, P. H., Creinin, M. D., Reeves, M. F., Cwiak, C., Esprey, E.,  
& Jensen, J. T. (2015). Prophylactic ibuprofen does not improve pain  
with IUD insertion: a randomized trial. Contraception, 91(3), 193-197. 
Design/Method Randomized, double-blind, placebo-controlled trial. 
Population 202 women, nulliparous or multiparous, 18 years and older. 
Variables/Intervention Oral ibuprofen 800 mg or placebo 30 to 45 min prior to IUD insertion. 
Measurement 100-mm visual analog scale to measure pain (0 = no pain, 100 = worst  
imaginable).  
Data analysis Using a two-sample t test, this sample size would provide 80 % power  
at an alpha of 0.05 to identify a 8-mm difference on a 100-mm VAS  
assuming a standard deviation of 20 mm. Differences compared using  
Fisher's Exact test, Chi-squared test or t test. A t test used to evaluate  
mean pain, reported as median as data not normally distributed. SPSS  
version 17.0 and SAS software. 
Findings No significant difference; the median pain score was 41.5 mm in the  
placebo group and 38.0 mm in the ibuprofen group (p = .50).  Mean and  
median pain scores did not differe between placebo and ibuprofen when  
nulliparous or parous were evaluated separately; however, overall  
median pain scores were 17.5 mm higher in nulliparous women (p =  
.004). Pain decreased in a linear pattern as parity increased from 0 to ≥ 3  
in multivariate analysis.  
Worth to practice Ibuprofen 800 mg administered 30 - 45 mins prior to IUD insertion does  
not decrease pain with IUD insertion. Harms without evidence of  
benefit include elevated risk of side effects and anxiety about expected  
pain and increased complexity of scheduling. Study did not address pain  
in the hours after placement, possible may have decreased pain in the  
hours following the procedure. Ibuprofen may require 2 h to reach  
maximum blood levels.Power to evaluate effects for both nulliparous  
and multiparous women. Sample size was sufficient to detect a  
difference in VAS score of 14 mm in nulliparous, and a 10 mm in  
parous women.  
Level of evidence I 
Notes  Good discussion of predictors of pain, comparison of nullip versus  
multip pain levels valuable for project literature review. 
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Citation Bednarek, P. H., Micks, E. A., Edelman, A. B., Li, H., & Jensen, J. T.  
(2013). The effect of nitroprusside on IUD insertion experience in  
nulliparous women: A pilot study. Contraception, 87, 421-425. 
Design/Method Randomized, double-blinded, placebo-controlled pilot study. 
Population 24 nulliparous aged 18 to 45 years. 
Variables/Intervention Nitroprusside 10 mg compounded into a 1 % aqueous gel or placebo  
intracervically immediately prior to IUD insertion.  
Measurement 100-mm visual analog scale (VAS; 0 = no pain, 100 mm = worst  
imaginable pain). Technique standardized with use of 2 mL  
lidocaine into tenaculum site. 
Data analysis Group sizes of 12 each to achieve 82 % power to detect a 30-mm  
difference between groups and a one-sided α of 0.05 given a pooled  
standard deviation of 28 mm.  
Fisher's Exact test, χ2 test or t test to compare baseline differences.  
Repeated-measures approach for comparing outcomes on VAS. Mena  
VAS scores presented.  
Findings A 15 - 20 mm reduction in the VAS score is considered clinically  
important. No significant differences between mean pain scores at IUD  
insertion (mean = 74 mm, SD = 18 for placebo, mean = 61 mm, SD =  
26 for nitroprusside, p = 0.18) or for any other time during the  
procedure. Mean satisfaction score with pain control was 64.5 mm in  
the nitroprusside group versus 82.4 mm in the placebo group (p = .20).  
Provider insertion difficulty on the VAS was similar in the two groups  
(26.5 ± 27.3 for placebo and 32.4 ± 22.7 for nitroprusside group, p =  
.57).  
Worth to practice Intracervical administration of 10 mg nitroprusside gel immediately  
before IUD insertion does not provide a clinically relevant reduction in  
pain with IUD insertion in nulliparous women. Pilot study showing a 14  
mm difference in mean pain scores which is less than the 15 to 20 mm  
considered to be clinically significant. Results from this pilot study do  
not support benefit for intracervical nitroprusside.  
Level of evidence I 
Notes  Small exploratory study, this intervention may raise concern of harm  
and does not support benefit of nitroprusside. 
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Citation Castro, T. V., Franceschini, S. A., Poli-Neto, O., Ferriani, R. A., Silva  
de Sa, M. F., & Vieira, C. S. (2014). Effect of intracervical anesthesia  
on pain associated with the insertion of the levonorgestrel-releasing  
intrauterine system in women without previous vaginal delivery: A  
randomized controlled study. Human Reproduction, 29(11), 2439-2445. 
Design/Method Randomized, open, parallel-group clinical trial.                                             
Clinics Hospital of the Medical School of Rebeirao Preto, Brazil. 
Population 100 women, nulliparous or without previous vaginal delivery. 
Variables/Intervention 400 mg ibuprofen one hr prior to insertion or 1.8 mL of 2% lidocaine to  
cervix equally divided among four injection sites 5 min before IUD  
insertion.  
Measurement Visual analog scale (VAS) 0 = no pain, 100 = worst pain imaginable;  
qualitatively analyzed (0 - 30 mm: mild pain, 40 - 60 mm: moderate  
pain and 70- 100 mm: severe pain). Ease of insertion rated as easy of  
difficult.   
Data analysis 80 subjects required, alpha of 5% and test power of 80%, considered a  
10% difference to achieve clinical relevance. Chi-squared test for  
qualitative variables, Student's t test for normally distributed  
quantitative variables. Linear mixed-effects model to evaluate paired  
variables. Logistic regression performed for covariates. Level of  
significance set at 5%. SAS 9.0 software.  
Findings Pain , level of discomfort, and difficulty of insertion did not differ  
between the groups. Difference between mean pain level in intracervical  
anesthetic group and NSAID group was < 10%. Intracervical anesthesia  
reduces moderate/severe pain by 40% [adjusted OR: 0.6 (95% CI: 0.2 -  
1.4)] but without statistical significance.  
Worth to practice Use of injectable intracervical anesthetic compared with NSAID is not  
associated with pain relief. Pain no different when injectable  
intracervical anesthetic or NSAID used in nulliparous women or in  
those without previous vaginal delivery. Although statistically  
insignificant, intracervical anesthesia reduced the risk of  
moderate/severe pain by 40% compared with the use of a NSAID.  
Level of evidence I 
 
 
 
 
 
 
 
 
 
 
 
 
MANAGEMENT OF PAIN DURING INTRAUTERINE DEVICE 58 
 
 
Citation Chor, J., Bregand-White, J., Golobof, A., Harwood, B., & Cowett, A.  
(2012). Ibuprofen prophylaxis for levonorgestrel-releasing intrauterine  
system insertion: a randomized controlled trial. Contraception, 85, 558- 
562. 
Design/Method Randomized, double-blind, placebo-controlled trial. 
University of Illinois Medical Center. 
Population 81 nulliparous or parous women, 18 years and older.  
Variables/Intervention 800 mg ibuprofen or placebo 45 min prior to IUD insertion. 
Measurement 10-cm visual analog scale (VAS, endpoints 0 = no pain and 10 =  
unbearable. Providers completed short questionnaire on experience with  
ease of insertion and need for dilation. 
Data analysis Sample size of 37 participants in each group to detect a difference of 1.5  
cm in the VAS assessment of pain with a 80% power and an alpha of  
0.05. Mean pain data using χ2 for categorical data and t test or Wilcoxon  
signed-rank test for continuous data using a two-tailed p value of .05.  
SAS version 9.2.  
Findings Mean pain scores at time of IUD insertion did not differ significantly  
between the placebo and ibuprofen groups (3.34 vs. 3.69 respectively; p  
= .91.   
Worth to practice Results are consistent with two trials that also failed to find a difference  
in pain at time of insertion between women who received ibuprofen or  
placebo. Pain of IUD insertion similar between women who received  
either ibuprofen or placebo. Mean interval from premedication with  
ibuprofen to insertion was 43 min; possible that medication was not  
given long enough prior to IUD insertion to have adequate effect (peak  
serum levels attained at 1-2 h after administration). 
Level of evidence I 
Notes  No significant differences in distribution of practitioner type, resident  
physicians placed 80% of IUDs. Mean insertion pain levels in both  
study groups (3.3 with placebo and 3.9 with ibuprofen) were higher than  
level reported by Hubacher et al (2006). 
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Citation Cirik, D. A., Taskin, E. A., Tuglu, A., Ortac, A. S., & Dai, O. (2013). 
Paracervical block with 1% lidocaine for pain control during 
intrauterine device insertion: A prospective, single-blinded, controlled 
study. International Journal of Reproductive Contraception Obstetrics 
and Gynecology, 2(3), 263-267. 
Design/Method Prospective, single-blinded, controlled study 
Population 95 women aged 18-45 years nulliparous and parous 
Variables/Intervention 10 mL 1% lidocaine paracervical block or 10 mL 0.9% NaCl 
paracervically injected as placebo, or no analgesia before IUD insertion. 
Measurement Visual pain scale with no pain graded as 0 and the worst pain ever as 10.  
Data analysis SPSS version 13.0. Demographic variables compared with either 
ANOVA or Kruskal-Wallis tests. The Chi-square test for categorical 
variables. Tukey correlation analysis done with Spearman's correlation 
test. Significance level set at p value < 0.05. 
Findings Median pain scores during IUD insertion were 2, 6, and 6 respectively, 
in the paracervical block, placebo, and no treatment groups. Pain scores 
in the paracervical block group were significantly lower (p = 0.001)  
Worth to practice Paracervical block is an easy, safe, and effective method of pain control 
during IUD insertion.  
Level of evidence I 
Notes  Compares block with placebo as well as with no intervention. 
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Citation Dijkhuizen, K., Dekkers, O. M., Holleboom, C. A., De Groot, C. M.,  
Hellebrekers, B. W., Van Roosmalen, G. J., … Helmerhorst, F. M.  
(2010). Vaginal misoprostol prior to insertion of an intrauterine device:  
A randomized controlled trial. Human Reproduction, 26(2), 323-329. 
Design/Method Double-blinded multicenter randomized controlled trial   
Outpatient gynecology department, the Netherlands 
Population  199 nulli- and parous ≥ 18 years women included 
Variables 400mcg misoprostol inserted vaginally or placebo 3h before IUD  
insertion. 
Measurement Visual analog scale (VAS) scale 'no pain' to 'worst imaginable pain' in  
millimeters, validated pain scale (Sriwantanakul et al., 1983). Difficulty  
of IUD insertion measured on 10-point scale 0 = extremely easy and 10  
as extremely difficult. Completed directly after insertion. 
Data analysis Sample size of 266 based on type 1 error of 0.05 and a power of 0.80.  
Power to detect side effects was 0.44. Pain scores and difficulty of  
insertion given as mean ± SD and compared using unpaired t tests.  
Statistical package for the Social Sciences, version 14. 
Findings Mean pain scores were similar in both groups; 46mm in the misoprostol  
group, and 40mm in the placebo group (P = 0.14). Difficulty of insertion  
did not differ 2.9 versus 2.8 in the misoprostol and placebo group (P =  
0.77). However, nulliparous participants pain scores were higher (57)  
than multiparous (30) participants, irrespective of the medication group  
(P = 0.001), and difficulty of insertion was also different between the  
two groups: 2.2 for multiparous versus 3.5 for nulliparous (P = 0.001).  
Side effects (most commonly abdominal cramping) significantly more  
frequent in misoprostol group 56 (56.6%) compared to 39 (42.4%) in the  
placebo group (P = 0.05, RR 1.3, 95% CI 1.0 - 1.7).  
Worth to practice Pain during IUD insertion was not influenced by pretreatment with  
misoprostol. Also, it did not reduce the number of failed insertions.  
Routine administration of misoprostol prior to IUD insertion is  
ineffective and might even cause side effects. 
Level of evidence 1 
Notes Inserted by interns, residents, midwives, gynecologists. Primary  
outcome measure was proportion of failed IUD insertions. Interestingly  
researchers reported pain scores as generally low when they were 40 to  
44mm! Discusses doses and routes. 
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Citation Edelman, A. B., Schaefer, E., Olson, A., Van Houten, L., Bednarek, P.,  
Leclair, C., & Jensen, J. T. (2011). Effects of prophylactic misoprostol  
administration prior to intrauterine device insertion in nulliparous  
women. Contraception, 84, 234-239. 
Design/Method Double-blind, randomized, placebo-controlled study 
Oregon Health and Science University 
Population 35 nulliparous aged 18 to 45 years. 
Variables/Intervention Misoprostol 400 mcg or placebo taken buccally 90 min prior to  
appointment time. Included local anesthesia at tenaculum site  
(benzocaine spray or 1 - 2 mL of 1% lidocaine injected). 
Measurement Subjects rated pain using 100 mm VAS (anchors 0 = none, 100 mm =  
worst imaginable at several time points. Providers recorded ease of  
insertion using VAS (anchors 0 = easy, 100 mm = extremely difficult). 
Data analysis 80% power at an α of 0.05 (one-sided for pain outcomes). Categorical  
and continuous data analyzed using χ2 and Student's t tests, respectively.  
SPSS software, version 17.  
Findings No significant difference in reported pain [misoprostol mean 65 mm  
(SD 21), placebo 55 mm (21), p = 0.83]. Provider-reported ease of  
placement was not significantly different between groups [misoprostol  
mean 24 mm (SD 19), placebo 29 mm (21), p = 0.5]. Subjects in  
misoprostol group reported more symptoms of nausea (misoprostol  
47%, placebo 5%, p = 0.05), and cramping (misoprostol 47%, placebo  
16 %, p = 0.04). 
Worth to practice Routine use of misoprostol does not reduce the pain a woman  
experiences, improve the ease of insertion for providers, or impact  
overall likelihood of successful placement. Women premedicated with  
misoprostol experience more adverse effects than benefits. The benefits  
of misoprostol do not outweigh the disadvantages, does not increase the  
likelihood of successful insertion, and does not reduce the pain  
associated with insertion.  
Level of evidence 1 
Notes  Since routine misoprostol does not improve outcomes and is associated  
with some proven and theoretical harms, the practice cannot be  
recommended for IUD insertion  
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Citation Esprey, E., Singh, R. H., Leeman, L., Ogburn, T., Fowler, K., & Greene,  
H. (2014). Misoprostol for intrauterine device insertion in nulliparous  
women: A randomized controlled trial. American Journal of Obstetrics  
and Gynecology, 210, 208.e1-5. 
Design/Method Randomized controlled double-blind trial 
University of New Mexico reproductive health clinic  
Population 85 nulliparous of any age (3 ineligible) total 82 Computer generated 8- 
block randomization sequences 
Variables/Intervention 400mcg buccal or placebo 2-8 hours before insertion. 
Measurement VAS pain scale 0 = none and 10 = worst imaginable pain, baseline,  
immediately after insertion, and before discharge from clinic. 
VAS scale (0 = easy and 10 = extremely difficult) for providers to rate  
ease of insertion. 
Data Analysis Power of 80% and α = 0.05 (2-tailed) with a sample size of 80. Fisher  
exact test for categorical and t test for continuous variables. Statistical  
significance set at P ≤ .05. SAS statistical software version 9.3. 
Findings Highest level of pain immediately after insertion was similar between  
the misoprostol (5.8 ± 2.0) and placebo (5.9 ± 2.0) groups (P = .94).   
The pain was described the pain as moderate, 50% in the misoprostol  
group and 40% in the placebo group (P = .6).                                      
Providers did not indicate any difference in ease of IUD insertion with a  
mean score of 2.2 ± 2.2 in the misoprostol group and 2.5 ± 2.2 in the  
placebo group (P = .54).  
Appraisal/Worth to 
practice 
No reduction in pain between women with 400 mcg of pre-procedure  
misoprostol, and no differences in provider perceptions of ease of  
insertion. Confirms IUD insertion is a painful procedure. Routine use of  
misoprostol in nulliparous women does not reduce pain with insertion or  
improve the ability to insert an IUD.  
Notes Providers were physicians skilled in IUD insertion. Also included 4- 
point Likert scale for patient preference for having IUD placed without  
delay for a med to decrease insertion pain (go to p.208e3 if want to  
include these results). Discussion of barriers. 
Level of evidence 1 
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Citation Heikinheimo, O., Inki, P., Kunz, M., Parmhed, S., Anttila, A., Olsson,  
S., ... Gemzell-Danielson, K. (2010). Double-blinded, randomized,  
placebo-controlled study on the effect of misoprostol on ease of  
consecutive insertion of the levonorgestrel-releasing intrauterine system.  
Contraception, 81, 481-486. 
Design/Method Double-blinded, randomized, placebo-controlled study. Subset of larger  
trial at 17 clinics in Finland, France, Ireland, and Sweden. 
Population 89, mostly parous, aged 23 to 45 years, opting for immediate  
replacement of IUD after 4y and 3 to 9mo. 
Variables/Intervention 400 mcg misoprostol or placebo sublingually 3 h before insertion. 
Measurement Pain by the patient rated as none, mild, moderate or severe. Ease of  
insertion by investigator rated as easy of difficult. 
Data analysis Sample size of 86 chosen based on statistical considerations (assumed  
proportion of easy insertions of 0.99 in the misoprostol and 0.79 in the  
placebo group), power of 80%. Means and SDs for continuous variables  
and frequency counts for categorical data. Fisher's Exact test for  
difficulty or ease of insertion. Significant when two-sided p value ≤ .05. 
Findings Women who received misoprostol did not report less pain than those  
who received placebo. No or mild pain was experienced by 16 (37.2%)  
and 16 (34.8%) receiving misoprostol and placebo, respectively. Severe  
pain was reported by 10 (23.3%) in the misoprostol group and by 5  
(10.9%) in the placebo group. Sublingual misoprostol did not have a  
significant effect on the ease of insertion (p = 1.00) and the overall pain  
experience did not differ between the two groups; more severe pain was  
reported following misoprostol.  
Adverse events (oral pain, nausea and diarrhea, or uterine contractions)  
were seen in significantly more women treated with misoprostol (n =  
22) than with placebo (n = 5)(51.2% vs. 10.9%).  
Worth to practice Study results do not support routine use of misoprostol to facilitate IUD  
insertion. Cervical priming with sublingual misoprostol 3 h prior to  
insertion did not result in improvement in ease of insertion, and there  
was no difference in pain between the misoprostol and placebo groups,  
yet severe pain was reported more frequently in the misoprostol group. 
Level of evidence 1 
Notes  11 well experienced and trained providers. Evaluated insertion  
immediately after removal of first IUD where may be increased risk for  
difficult insertion after long-term use of LNG-IUD (as with  
perimenopausal or nulliparous women). Main outcomes were ease or  
difficulty of insertion.  
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Citation Ibrahim, Z. M., & Ahmed, W. A. (2013). Sublingual misoprostol prior  
to insertion of a T380A intrauterine device in women with no previous  
vaginal delivery. The European Journal of Contraception and  
Reproductive Health Care, 18, 300-308. 
Design/Method Single-blind randomized controlled trial. 
Gynecology Clinic of Suez Canal University Hospital, Egypt. 
Population 200 parous women delivered by cesarean section. 
Variables/Intervention 400 mcg misoprostol sublingually and 100 mg diclofenac potassium  
orally or only 100 mg dicolofenac orally one hour prior to insertion. 
Measurement Visual analog scale (VAS) 0 to 10, 0 = no pain, and 10 = worst possible  
pain imaginable. Insertion classified by investigator as 'easy', 'usual',  
'difficult', or 'failed'.  
Data analysis Mean values, standard deviations, frequencies, and percentages.  
Student's t test and analysis of variance for significance of difference,  
Chi-squared test for categorical data.  A probability value less than 0.05  
was considered statistically significant. Microsoft Excel 2003 and SPSS  
version 15.  
Findings There were no significant differences in patient-reported pain  
experienced at IUD insertion. VAS pain estimation for diclofenac +  
misoprostol group median was 7 (2.5 - 10) and for the control group  
was 6.5 (0 - 10); p = 0.8.  
Ease of insertion was not significantly different between the two groups. 
Nausea was the most frequent side effect noted in 19.7 % of women in  
the diclofenac + misoprostol group, as compared to only 4.4 % of those  
pretreated solely with diclofenac. (see table pg 304 to add significance  
for headache and cramping) 
Worth to practice IUD was given only one hour after sublingual misoprostol intake.  
"Adding sublingual misoprostol to diclofenac may cause side effects  
without providing the benefit of an easier and/or more successful  
insertion" (p. 307). Routine pretreatment with misoprostol is not  
recommended. 
Level of evidence 1 
Notes  All gynecologists with at least three years experience inserting IUDs.  
Primary outcome measure was success of failure of insertion. Secondary  
outcome measures were ease of insertion and pain. 
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Citation Karabayirli, S., Ayrim, A. K., & Muslu, B. (2012). Comparison of the  
analgesic effects of oral tramadol and naproxen sodium on pain relief  
during IUD insertion. The Journal of Minimally Invasive Gynecology,  
19(5), 581-584. 
Design/Method Randomized, double-blinded, clinical trial.                                            
University-affiliated hospital, single-center. 
Population 103 multiparous women aged 18 to 49 years.  
Variables/Intervention Oral tramadol 50 mg (n = 35) or naproxen sodium 550 mg (n = 34) or  
placebo (n = 34) one hour before IUD insertion.  
Measurement 10 point visual analog scale with a score of 10 meaning the "worst  
imaginable pain".  
Data analysis Sample size each group 29, with a power of 80 % and an α of 0.05.  
Software used included SigmaXL version 6.1, Power and Sample Size  
Calculations for a One-Way ANOVA, and SPSS version 17.0. Tested  
for normality using Kolmogorov-Smirnov test with a Lilliefors  
significance correction. Differences analyzed using analysis of variance.  
Homogeneity calculated using Levene test. Posthoc analysis using  
Tukey honestly significantly different post hoc test. The χ2 or Fisher  
exact test to analyze categorical variables. Data given as mean (SD) and  
p value of < .05 considered significant. 
Findings VAS scores were significantly different between the 3 groups (p =  
.001). Pain scores in the tramadol group were significantly lower than in  
the naproxen group (p = .001), and scores in the naproxen group were  
significantly lower than in the placebo group (p = .001). The mean (SD;  
95% CI) VAS pain score of 2.31 (0.60; 2.09-2.53) in the tramadol group  
was significantly lower than in the naproxen group (2.94 [0.71; 2.69- 
3.18]) and the placebo group (4.88 [1.0; 4.54-5.22]).  
Worth to practice Tramadol 50 mg demonstrated superior analgesia over naproxen and  
placebo during IUD insertion. Naproxen demonstrated significantly  
lower mean pain scores than placebo. Oral administration of naproxen  
550 mg or Tramadol 50 mg orally one hour prior to IUD insertion can  
be used to relieve pain; however tramadol is more effective.  
Level of evidence I 
Notes  When tramadol and naproxen were compared, the tramadol mean scores  
were significantly lower, although this may not be clinically significant  
as the pain scores in both groups were similar. Study does not take into  
account nulliparity.  
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Citation Lathrop, E., Haddad, L., McWhorter, C. P., & Goedken, P. (2013). Self- 
administration of misoprostol prior to intrauterine device insertion  
among nulliparous women: A randomized controlled trial.  
Contraception, 88, 725-729. 
Design/Method Double-blind, randomized, controlled trial. 
Population 71 nulliparous 18 years or older.  
Variables/Intervention 400 mcg misoprostol or placebo bucally 2 - 4 h prior to procedure  
appointment time.  
Measurement Pain score using 100-mm validated visual analog scale (0 = none, 100  
mm = worst imaginable).  
Provider rated ease of insertion on 100-mm scale (0 = extremely easy,  
100 mm = impossible).  
Data analysis 80% power to detect a mean difference of at least 16 mm in participant-  
reported pain using VAS with an α of .05 assuming 23-mm standard  
deviation. Chi-squared analysis of Fisher's Exact Tests to detect  
differences for categorical variables. Mann-Whitney to sompare  
medians for continuous variables. Descriptive statistics using SPSS  
version 20.  
Findings Patients in the misoprostol group reported significantly more pain than  
those in the placebo group immediately before (p = .0001) and after (p =  
.044). 
IUD insertion median and range of perceived ease of insertion reported  
by providers for the misoprostol group was 21 mm (0 - 100) and 21 mm  
(0 - 68) for the placebo group which was not significantly different (p =  
.75).  
Worth to practice Misoprostol increased reported pain with and after IUD insertion and  
did not decrease provider perception of ease of insertion of IUDs in  
nulliparous women, and should not be recommended routinely for  
cervical priming prior to nulliparous IUD insertion.  
Level of evidence 1 
Notes  All obstetrician gynecologists with extensive family planning training.  
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Citation Maguire, K., Davis, A., Rosario Tejeda, L., & Westhoff, C. (2012).  
Intracervical lidocaine gel for intrauterine device insertion: A  
randomized controlled trial. Contraception, 86, 214-219. 
Design/Method Randomized, double-blind, placebo-controlled trial.  
Columbia University medical Center, New York. 
Population 200 women, aged 18 to 45 years, nulliparous and parous. 
Variables/Intervention 2% lidocaine gel or matching placebo gel (Surgilube) soaked onto a  
cotton swab and inserted into the cervix up to the internal os for 60 secs. 
Measurement Participants rated pain on a 100- mm VAS.  
Data analysis 110 women needed assuming two-sided alpha of 0.05 and 90% power.  
200 particpants allowed 80% to detect a 20- mm difference on the VAS.  
Used t tests or Wilcoxon-Mann-Whitney tests to evaluate pain scores.  
Linear regression to examine predictors of pain. SAS 9.2 statistical  
software. 
Findings Pain scores were comparable in both groups: mean 50.9 mm (SD 32) for  
the lidocaine group and 51.0 mm (SD 31) for the placebo groups (p =  
.98). Stratified for parity, stratified analysis showed no treatment effect.  
Worth to practice No significant difference in mean pain with intracervical lidocaine gel  
compare to placebo, whether nulliparous or parous. Two percent  
lidocaine did not decrease IUD insertion pain.  
Level of evidence I 
Notes  Multivariate analyses identified longer time since last pregnancy, lower  
parity, higher anticipated pain, and dysmenorrhea as predictors of pain.  
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Citation McNicholas, C. P., Madden, T., Zhao, Q., Secura, G., Allsworth, J. E.,  
& Peipert, J. F. (2012). Cervical lidocaine for IUD insertional pain: a  
randomized controlled trial. American Journal of Obstetrics and  
Gynecology, 207, 384.e1-6. 
Design/Method Randomized, double-blind, controlled trial. Washington University. 
Population 199 women aged 18 to 45 years, equal number of nulliparous and  
parous women. 
Variables/Intervention 0.5 - 1 mL of 2% lidocaine gel to ectocervix at planned tenacum site, 2 -  
3 mL via 20G angiocatheter into endocervical canal 3 mins prior to  
insertion of IUD.  
Measurement 10- point visual analog scale. 
Data analysis Mean pain score of 4 (SD = 2.5) for women undergoing IUD insertion  
found in preliminary data from the Contraceptive CHOICE project. 50%  
reduction in the mean pain score considered clinically important.  
Required 86 women to reach 90% power with an alpha (type 1) error of  
0.05. SAS 9.2 software. Significance set at p < .05. Continuous  
variables summarized as means, medians, ranges, and SD. Categorical  
variables presented as frequencies. Continuous variables analyzed with  
Student t test. χ2 and Fisher exact tests to analyze categorical variables.  
Pain scores not normally distributed, analyzed using Wilcoxon rank sum  
test.  
Findings Insertional pain scores between nulliparous and parous women were  
significantly different regardless of intervention. Median pain score in  
placebo was 7 among nulliparous women and 5 among parous women,  
and in the lidocaine group median pain was 6 in nulliparous women and  
4 in parous women. No difference in insertional pain between the  
placebo and lidocaine groups: median pain score was 6 in placebo arm  
and 5 in the lidocaine arm (p = .20).  
Worth to practice Despite the finding that nulliparous women had significantly higher pain  
scores, reported pain was not different for nulliparous women  
randomized to intracervical lidocaine. Innovative delivery mechanism  
using angiocatheter allow gel to be placed the length of the cervical  
canal. Physiologically plausible intervention allowing 3 mins before  
insertion: time chosen based on pharmacologic properties of the gel and  
reasonable amount of time to leave speculum in place. With more time  
may see an improvement of pain scores but how long will patient  
tolerate having speculum in place or having multiple speculum exams if  
removed after anesthetic administration then replaced for IUD insertion.  
Level of evidence I 
Notes  All participants received ibuprofen approximately 10 mins prior to  
procedure to minimize postprocedure cramping.  
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Citation Micks, E. A., Jensen, J. T., & Bednarek, P. H. (2014). The effect of  
nitroglycerin on the IUD insertion experience in nulliparous women: A  
pilot study. Contraception, 90(1), 60-65. 
Design/Method Randomized, double-blinded, placebo-controlled pilot study. 
Population 24, mostly nulliparous. 
Variables/Intervention Nitroglycerin 0.5 mg gel (1 mL) or placebo gel applied vaginally 30 min  
prior to IUD placement. 
Measurement Participants rated their pain using a 100-mm visual analog scale (0 mm  
= no pain, 100 mm = most pain imaginable). Providers rated ease of  
insertion using the 100-mm VAS (0 mm = very easy, 100 mm = very  
difficult).  
Data analysis Mean and standard deviation reported, all p values calculated using  
Fisher's Exact test or Student's t test.  
Findings The mean pain score with IUD insertion was 55 mm [standard deviation  
(SD) = 29.7 mm] in the placebo group and 57.4 mm (SD 22.1 mm) in  
the nitroglycerin group (p = .82).                                                              
No difference in ease of insertion reported by providers. 
Worth to practice Results do not support the use of nitroglycerin prior to IUD insertion.  
Vaginal administration of 0.05 mg nitroglycerine gel 30 minutes prior to  
IUD insertion does not appear to decrease patient reported pain among  
nulliparous women or ease insertion for providers.  
Level of evidence 1 
Notes  Possible that time interval between nitroglycerine application and IUD  
insertion or dose of medication was not sufficient to show a beneficial  
effect, although prolonged interval or higher doses may cause more side  
effects, may not be practical, or acceptable to the provider or the patient.  
Pilot study, small number of participants, provides exploratory data.  
Subjects had the option of taking ibuprofen prior to the procedure; may  
be an important cofounder, since it was taken by more subjects in the  
nitroglycerin group.  
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Citation Mody, S. K., Kiley, J., Rademaker, A., Gawron, L., Stika, C., &  
Hammond, C. (2012). Pain control for intrauterine device insertion: A  
randomized trial of 1% lidocaine paracervical block. Contraception, 86,  
704-709. 
Design/Method Randomized controlled trial, blok randomization stratified by parity.  
Northwestern Medical Faculty Foundation practice (single clinical site),  
Chicago, IL. 
Population 50 nulliparous and multiparous women. 
Variables/Intervention 2 mL 1% lidocaine at tenaculum site and 10- mL  paracervical  
anesthetic, 3 min waiting period prior to insertion, or no analgesia  
(saline injection not used as a control as researchers wanted to compare  
block to standard of care).  
Measurement Participants rated pain on visual analog scale graded 0 (no pain) to 10  
(worst pain). Providers not blinded. Senior resident, advanced practice  
nurses, or attending physician inserted IUDs. Potential side effects  
(metallic taste and tinnitus) recorded.  
Data analysis Sample size of 38 needed calculated based on a 20- mm difference on  
VAS to be clinically significant, 80% power. Two-tailed test and type 1  
error rate of 5% assumed. Independent-sample t test for continuous data  
or Fisher's Exact Test for dichotomous data. Wilcoxon rank sum test  
used since data were non-normal. Data reported as percentages, means  
with standard deviations and 95% confidence intervals (CI) or medians.  
Findings Lower median pain score in paracervical block group (24 mm)  
compared with no analgesia (62 mm) during IUD insertion, but not  
statistically significant (p = .09). Statistically significant decrease in  
pain during tenaculum placement (p = .008) when local administered at  
12'clock. Standard deviation was 27.5 mm in no analgesia group and  
35.9 mm in paracervical block group. 
Worth to practice Study showed large standard deviation for pain scores emphasizing that  
patients have varying pain with IUD insertions and methods to alleviate  
pain are worthwhile. Some participants did report high levels of pain  
with paracervical block administration (median 40.0) which may  
dissuade providers and patients from using it even if it helps decrease  
pain during IUD insertion (median pain with block was lower).  
Level of evidence I 
Notes  Provided data and insight regarding specific characteristics associated  
with pain during IUD insertion: more pain in multiparous women with  
fewer vaginal deliveries and greater time since last pregnancy, low pain  
associated with breastfeeding and higher gravidity.  
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Citation Mohammad-Alizadeh-Charandabi, S., Seidi, S., & Kazemi, F. (2012).  
Effect of lidocaine gel on pain from copper IUD insertion: A  
randomized double-blind controlled trial. Indian Journal of Medical  
Sciences, 64(8), 349-355. 
Design/Method Randomized, controlled, clinical trial.   Public health center, Iran.  
Population Aged 18 to 49 years 
Variables/Intervention Intracervical lidocaine gel, lubricant gel, or no intervention. 
Measurement Visual analog scale measured from 0 = no pain to 10 = worst imaginable  
pain.  
Data analysis 96 subjects needed to detect 20% reduction in pain with to-sided 5%  
significance level and power of 90%. One-way ANOVA and Kruskal- 
Wallis for quantitative variables. Linear regression to determine effect  
of lidocaine, p < .05 considered significant. SPSS/13 statistical software.  
Findings Mean pain score was 3.5, approximately half (46%) reported moderate  
pain. No statistically significant difference in mean pain scores between  
the 3 groups: 3.4 in lidocaine gel group, 3.4 in the lubricant gel, and 3.7  
in the no intervention group.  
Worth to practice 2% lidocaine gel did not significantly reduce IUD insertion pain. Gel  
was used intracervically, not on the outer part of the cervix where  
tenaculum placed.  
Level of evidence I 
Notes  Article provides discussion on pain pathways relating to IUD insertion. 
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Citation Nelson, A. L., & Fong, J. K. (2013). Intrauterine infusion of lidocaine  
does not reduce pain scores during IUD insertion. Contraception, 88,  
37-40. 
Design/Method Randomized, double-blind, placebo-controlled, investigator-funded pilot  
study. Women's Health Care Clinic, Los Angeles Biomedical Research  
Institute at Harbor-UCLA Medical Center.  
Population 40 women. 
Variables/Intervention 1.2 mL of 2% lidocaine or normal saline infused 3 min prior to IUD  
insertion using a Pipet Curet endometrial aspirator with a 4- mm outer  
diameter into 3 parts of endometrial cavity: lower one third, middle and  
top of cavity. Two experienced clinicians.  
Measurement Participants rated pain on a scale of 0 (no pain) to 9 (worst pain in life).  
Data analysis Sample size selected arbitrarily for convenience due to budget and time  
constraints. Would need 418 subjects to detect a significantly significant  
difference in pain scores, assuming an 80% power and a 5% alpha error.  
Statistical significance calculated using t test to compare means of  
continuous variables with p < .05 as the level of significance.  
Findings Mean pain scores did not differ between the lidocaine group (mean  
score 3.0) and the normal saline group (mean score 3.7) (p = .40).  
Eleven of the women took NSAIDs before insertion, but their mean pain  
scores (3.89) did not differ significantly from those who did not take  
NSAIDs (3.25) (p < .76). Mean pain scores who had lidocaine and  
NSAIDs (3.8) did not differ from those who received normal saline and  
had no NSAIDs (3.7) (p = .86). 
Worth to practice Pilot study, does not demonstrate any advantage for infusing small  
amounts of lidocaine into the endometrial cavity to reduce pain  
associated with IUD insertion. 
Level of evidence I (pilot study) 
Notes  Provides data on mean pain scores and percentage of women  
experiencing moderate to severe pain with IUD insertion (pain ≥ 3). 
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Citation Ngo, L. L., Ward, K. K., & Mody, S. K. (2015). Ketorolac for pain  
control with intrauterine device placement. Obstetrics and gynecology,  
126(1), 29-36. 
Design/Method Randomized, double-blind, placebo-controlled trial. University of  
California San Diego Women’s Health Clinics. 
Population 67 nulliparous or multiparous women aged 18 to 51 years.  
Variables/Intervention Ketorolac 30 mg or placebo of normal saline injected into upper outer  
quadrant of gluteus muscle 30 min prior to insertion. 
Measurement Pain level on a visual analog scale from 0 cm (no pain) to 10 cm (worst  
pain possible). Questionaire at 15-minute post procedure to assess  
possible side effects from study drug. Providers completed  
questionnaire including level of training, type of IUD, purpose, uterine  
position, and any complications.  
Data analysis 57 participants needed to obtain 80% power with a 5% α error rate.  
Power calculation based on previous studies using 10-cm VAS. Data  
analyzed based on an intention-to-treat analysis. Pain scores (continuous  
variables) compared using Wilcoxon rank-sum test as had a nonnormal  
distribution. The χ2 for categorical variables and t test or Wilcoxon rank- 
sum test for continuous variables. PASW Statistics 18 and SAS 9.4  
software. 
Findings No difference in median pain scores during IUD placement between the  
placebo compared with ketorolac groups (5.2 compared with 3.6 cm, p  
= .99). Decrease in median pain scores after IUD insertion at 5 minutes  
(2.2 compared with 0.3 cm, p ≤ .001) and 15 minutes (1.6 compared  
with 0.1 cm, p ≤ .001). Nulliparous women (n = 16) had a decrease in  
pain scores with IUD placement (8.1 compared with 5.4 cm, p = .02).  
Post procedure health questionnaire revealed significantly more  
participants in placebo group received acetaminophen at 15 minutes  
after IUD insertion compared with the ketorolac group (52% compared  
with 21%, p = .02). 
Worth to practice Ketorolac does not reduce pain with IUD insertion but does reduce pain  
at 5 and 15 minutes after placement. Study does support intramuscular  
ketorolac for decreasing pain after IUD insertion. Study not powered to  
detect a difference less than 2.0 cm. Nulliparous participants showed a  
decrease in pain, but this study was not powered for subgroup analysis  
for parity, and small sample size of 16 nullips – may be result of chance  
and may not be generalizable. Ketorolac relatively inexpensive  
(approximately $1 per dose), can be stocked in clinics, wait time of 30  
mins compared with 1 h for oral NSAIDs, analgesia lasting 4 – 6 h.  
Need for potentially painful IM injection and in-clinic wait time of 30  
mins.  Health care provider must be available to administer the  
injection.  
Level of evidence I 
Notes  Clinically significant difference in VAS defined as 1.3 – 2.0 cm,  
researchers used a difference of 2.0 cm. Questionaire revealed few  
minor side effects from study drug. Majority of participants felt pain  
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form injection was “not as bad” as pain from IUD placement (71%  
compared with 81%); however, participants (22% in placebo group and  
18% in ketorolac group) reported injection pain was as painful as IUD  
placement. Median pain scores higher in nulliparous subgroup  
compared with multiparous subgroup (8.1 compared with 3.7 in placebo  
arm and 5.4 compared with 2.5 cm in ketorolac arm). Maximal effect of  
ketorolac at 1 – 2 h, but study done at time of onset, 30 mins.  
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Citation Scavuzzi, A., Souza, A. S., Costa, A. A., & Amorim, M. M. (2013).  
Misoprostol prior to inserting an intrauterine device in nulligravidas: A  
randomized clinical trial. Human Reproduction, 28(8), 2118-2125.  
Design/Method Randomized, double-blinded clinical trial. 
Population 179 nulligravid of reproductive age. 
Variables/Intervention Misoprostol 400 mcg or placebo into posterior vaginal fornix by  
investigator 4 h prior to IUD insertion. 
Measurement Women judged pain subjectively using VAS 0 = absence of pain, 10 =  
worst pain imaginable, later dichotomized into absent/mild (0 - 5) and  
moderate/severe (6 - 10). Subjective difficulty as reported by the  
investigator.  
Data analysis Sample size of 152 deemed necessary using OpenEpi software program.  
Distribution tables of frequency for categorical variables, and measures  
of central tendency and dispersion calculated for numerical variables.  
Fisher's exact test and χ2 test of association and two=tailed values for all  
tests. Risk ratios (RR) calculated as a measure of relative risk with  
relevant 95% confidence intervals (CI). Number needed to treat (NNT)  
and number needed to harm (NNH) calculated with respective 95% CI. 
Findings The misoprostol group had a 44% reduction in moderate-to-severe pain  
compared with the placebo group (RR = 0.56; 95% CI: 0.41 - 0.76;  
NNT = 3; P = 0.00004). Significant differences were found with less  
difficulty in inserting the IUD (RR = 0.49; 95% CI: 0.33 = 0.72; NNT =  
3; P = 0.00001). No significant differences in frequency of side effects  
such as nausea, vomitinf, hyperthermia, and diarrhea, but there was a  
significant increase in cramps in the misoprostol group compared with  
placebo (RR = 1.40; 95% CI: 1.05 - 1.86; NNH = 6; P = 0.002). 
Worth to practice Use of misoprostol 400 mcg vaginally inserted by the provider four  
hours pre-insertion of IUD was found to be associated with less  
subjective difficulty in inserting the IUD in nulligravidas, and less pain  
as reported by the women; however, there was a greater incidence of  
cramps. The effect of misoprostol on the cervix makes its use a feasible  
proposition for certain gynecological procedure, but may not be feasible  
/ may be detrimental to overall choice of this method due to 4 h interval  
between dosing and insertion. Use it in group of women provider deems  
necessary to reduce pain and facilitate insertion ease. NNT to evaluate  
actual benefits in clinical practice: for every three IUD insertions, with  
prior use of misoprostol, one woman would have an easier procedure.  
Level of evidence 1 
Notes  Principal investigator inserted all interventions and IUDs. Good  
discussion of how misoprostol could work and rationale for using  
vaginally vs orally at time interval of 4 h. 
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Citation Singh, R., Thaxton, L., Carr, S., Leeman, L., Schneider, E., & Esprey,  
E. (2015). Nitrous oxide for intrauterine device insertion in nulliparous  
women: A randomized controlled trial.  
Design/Method Double blind, randomized controlled trial 
Population 80 nulliparous women, aged 13 - 45 years 
Variables/Intervention 50/50 nitrous oxide with oxygen or oxygen alone through a mask 
Measurement 100-mm visual analog scale for pain. Satisfaction with pain  
management on a 5-point Likert scale  
Data analysis Sample of 80 women needed to determine a clinically significant  
difference in mean VAS scores of 15 mm with 80% power and α = 0.05.  
Mean scores.  
Findings Mean maximal pain scores were similar between groups  
(54±25mm[nitrous oxide] compared with 55±21 [oxygen]; p =.85).  
Women in nitrous group were more satisfied with their pain  
management (67.5% vs 42.5%; p = .04) on the Likert scale. 
Worth to practice No adverse effects. Women expressed satisfaction even though it did  
not reduce their pain (anxiolytic). Sets in rapidly, inexpensive,  
noninvasive, easily reversible. 
Level of evidence I 
Notes  Nitrous works in so many pathways. Has analgesic and amnesic effects. 
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Citation Swenson, C., Turok, D. K., Ward, K., Jacobson, J. C., & Dermish, A.  
(2012). Self-administered misoprostol or placebo before intrauterine  
device insertion in nulliparous women. Obstetrics & Gynecology, 120,  
341-347. 
Design/Method Randomized controlled trial. 
Outpatient obstetrics and gynecology clinic, University of Utah. 
Population 105 nulliparous age 18 years or older. 
Variables/Intervention Misoprostol 400 mcg or placebo vaginally or bucally 3 - 4 hours before  
insertion.   
Measurement Pain rated by participants using validated 100-mm visual analog scale (0  
= none, 100 mm = worst imaginable). 
Healthcare provider addressed ease of insertion based on visual analog  
scale (0 = extremely easy, 100 mm = impossible).  
Data analysis Sample size and power calculation determined to detect a 15-mm  
difference in participant perceived pain. For α = 0.05 and 90 % power,  
50 participants needed in each group. Wilcoxon Mann-Whitney used  
because variables of interest failed to meet Shapiro-Wilks normality  
assumption. STATA version 10.0 software.  
Findings 94% chose to insert vaginally (n = 99), data was analyzed excluding  
buccal administration (n = 6). No significant difference in pain during  
IUD insertion. (p = .74). Pain significantly higher before IUD insertion  
in misoprostol group (mean 17.1 mm) versus the placebo group (mean  
4.7 mm); p = .003). 
Healthcare provider ease of insertion was not significantly different  
between the two groups (misoprostol mean 25 mm, placebo mean 27.4  
mm, p = .64).  
Worth to practice Self-administered misoprostol 3 - 4 hours before IUD insertion in  
nulliparous women does not reduce patient-perceived pain, and does not  
increase healthcare provider ease of insertion.  
Level of evidence 1 
Notes  Healthcare providers having placed 10 or more IUDs in past year. 
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Citation Tavakolian, S., Doulabi, M. A., Baghban, A. A., Mortazavi, A., &  
Ghorbani, M. (2015). Lidocaine-Prilocaine cream as analgesia for IUD  
insertion: A prospective, randomized, controlled, triple-blinded study.  
Global Journal of Health Science, 7(4), 399-404. 
Design/Method Prospective, randomized, controlled, triple-blinded study. 
Population 92 women, multiparous 
Variables/Intervention EMLA cream containing 25 mg lidocaine and 25 mg prilocaine or  
placebo cream applied to cervix using cotton swab, 7 minutes prior to  
IUD insertion. 
Measurement Visual analog score 10-cm where 0 means no pain and 10 the most  
severe pain. Tated as 0 for no pain, 1-3 for mild pain, 4-6 for average  
pain, 7-9 for severe pain and 10 for worst pain ever. 
Data analysis Descriptive and inferential statistics. Chi square and Fisher's exact test  
for demographic and confounding variables. Quantitative variables  
compared using independent t test or Mann-Whitney test. Significant if  
p < 0.05. SPSS 17 
Findings Significant difference in pain between the two groups 4.61±2.55 in the  
placebo group and 2.65±2.53 in the EMLA group; p < 0.001.  
Worth to practice Topical EMLA cream reduces pain during IUD insertion but seven  
minutes was allocated for the anesthetic to work. 
Level of evidence I 
Notes  Discusses differences in pain transmission in uterus versus cervix.  
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Citation Tornblom-Paulander, S., Tingaker, B. K., Werner, A., Liliecreutz, C.,  
Conner, P., Wessel, H., & Ekman-Ordeberg, G. (2015). Novel topical  
formulation of lidocaine provides significant pain relief for intrauterine  
device insertion: A pharmacokinetic evaluation and randomized  
placebo-controlled trial. Contraception, 103(2), 422-427. 
Design/Method Phase-I : single-arm pharmacokinetic study. Phase-II: randomized,  
double-blind, placebo-controlled trial studies. Karolinska University  
Hospital, Stockholm, and three public hospitals, Sweden.  
Population Women aged older than 18 years, no restrictions on previous childbirth. 
Variables/Intervention Phase-I: Single 8.5-mL dose of lidocaine gel (1 mL onto portio surface,  
2 mL into cervical canal, and 5.5 mL into uterine cavity) 5 minutes  
before IUD insertion.  
Phase-II: Lidocaine or a placebo gel with IUD insertion taking place  
within 5 mins.  
Measurement Phase-I: Blood samples at baseline, and at 5,10,20,30,60,120, and 180  
mins after lidocaine administration. Pain assessed on a 100-mm VAS. 
Phase-II: Patient rated maximum pain level on 100-mm VAS. 
Data analysis Phase-I: Sample size of 15 to determine pharmacokinetic parameters:  
maximum plasma concentration (Cmax), time taken to reach maximum  
concentration (tmax). Results presented as mean ± SD or absolute values. 
Phase-II: Sample size of 172 would provide statistical significance at  
the 5% level, and 90% power. Comparison performed using analysis of  
variance (ANOVA), expressed as mean difference with 95% confidence  
level. Stratified ANOVA to investigate relationships between VAS pain  
and IUD type, midwife, volume of lidocaine administered, and degree  
of discomfort.  
Findings Phase-I: Pharmacokinetic parameters were Cmax 351 ± 205 ng/mL, and  
tmax 68 ± 41 minutes). Considerable individual variation in absolute  
plasma levels; highest value for Cmax 725 ng/mL and lowest value was  
64.7 ng/mL. Pain scores on VAS were low, with mean values < 9 mm.  
Association between Cmax and pain relief observed, with almost  
complete pain relief in 6 of 7 women with Cmax > 350 ng/mL. No  
serious adverse events.                                                                                  
Phase-II: Mean VAS score for maximum pain significantly lower in the  
lidocaine group than in the placebo group (28.3 vs. 44.2; p < 0.001).  
Mean between-group difference was 15.0 representing a 36% reduction  
in VAS score in the lidocaine group. Significantly higher percentage in  
lidocaine group considered to be essentially pain-free (VAS score ≤10  
mm), and significantly lower percentage had moderate to severe pain  
(VAS score > 40 mm). Stratified ANOVA showed neither discomfort  
during administration of the study treatment nor IUD type influenced  
the effect of lidocaine.   
Worth to practice Study shows administration of lidocaine, as a short-acting 4% viscous  
solution, 5 minutes before insertion of an IUD provides pain relief.  
Benefits of lidocaine evident in several ways: significantly reduced  
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mean VAS score; high percentage reduction in mean VAS score; higher  
percentage of women with lower maximum pain; significantly higher  
percentage of women who were essentially pain-free; and a significantly  
lower percentage of women with moderate to severe pain. Duration of  
pain relief with lidocaine between 30 and 60 minutes.  
Level of evidence I 
Notes  Percentage of women reporting no or a little discomfort during  
administration of study drug was greater in the lidocaine group (63.6%)  
than in the placebo group (47.2%) representing a statistically significant  
difference (p = .023).  
 
